



King's Research Portal

DOI:

[10.1016/j.survophthal.2022.04.002](https://doi.org/10.1016/j.survophthal.2022.04.002)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Kirthi, V., Nderitu, P., Alam, U., Evans, J. R., Nevitt, S., Malik, R. A., Hopkins, D., & Jackson, T. L. (2022). The prevalence of retinopathy in prediabetes: A systematic review. *Survey of Ophthalmology*, 67(5), 1332-1345. <https://doi.org/10.1016/j.survophthal.2022.04.002>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Survey of Ophthalmology

The prevalence of retinopathy in prediabetes: a systematic review

--Manuscript Draft--

Manuscript Number:	SURVOPH-D-21-00042R2
Article Type:	Review article
Section/Category:	Retina/Vitreous
Keywords:	Prediabetes; impaired fasting glucose; impaired glucose tolerance; retinopathy; prevalence; epidemiology
Corresponding Author:	Varo Kirthi King's College London Denmark Hill, London UNITED KINGDOM
First Author:	Varo Kirthi
Order of Authors:	Varo Kirthi Paul Nderitu, FRCOphth Uazman Alam, PhD Jennifer Evans, PhD Sarah Nevitt, PhD Rayaz A. Malik, FRCP David Hopkins, FRCP Timothy L. Jackson, FRCOphth
Abstract:	<p>Diabetic retinopathy is a leading cause of vision loss globally. The current diagnostic thresholds for diabetes are still based on historic data correlating glycaemic parameters with retinopathy. However, an excess prevalence of retinopathy has also been reported in prediabetes. This systematic review aimed to determine the reported prevalence of retinopathy in adults with prediabetes. We performed searches using MEDLINE, EMBASE, PubMed, Web of Science, CINAHL, Google Scholar and the Cochrane databases from inception to 1 August 2020. We evaluated methodological quality and certainty of the evidence using a validated risk of bias tool and GRADE, respectively. Twenty-four studies (8759 participants with prediabetes) were included after screening 5994 abstracts and reviewing 98 full-text records. Nineteen studies (79%) reported population-based data. Retinopathy prevalence estimates ranged between 0.3-14.1% (median 7.1%, interquartile range 2.4-10.0%), with high variance in estimates due to differing screening methods, retinopathy grading protocols and study populations. We judged this as low-certainty evidence using GRADE, downgrading for risk of bias and inconsistency. From studies that compared both populations, post hoc analysis revealed a lower median retinopathy prevalence in normal glucose tolerance (3.2%, interquartile range 0.3-7.3%) than prediabetes (6.6%, interquartile range 1.9-9.8%). These data suggest an excess prevalence of retinopathy in prediabetes.</p>
Response to Reviewers:	Please find attached the final manuscript with some minor tracked changes and also a clean version. No changes have been made to the editorial revisions suggested.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 **TITLE**

2 The prevalence of retinopathy in prediabetes: ~~A~~ systematic review

3 **AUTHORS**

4 Dr Varo Kirthi FRCOphth ^{1,2}, Dr Paul Nderitu FRCOphth ^{1,2}, Dr Uazman Alam PhD ^{3,4,5}, Dr
5 Jennifer R. Evans PhD ^{6,7}, Dr Sarah Nevitt PhD ³, Prof Rayaz A. Malik FRCP ^{8,7}, Dr David
6 Hopkins FRCP ^{1,2}, Prof Timothy L. Jackson FRCOphth ^{1,2}

7 **Institutions:** ¹ King's College London, London, UK; ² King's College Hospital NHS
8 Foundation Trust, London, UK; ³ University of Liverpool, Liverpool, UK; ⁴ Liverpool
9 University Hospitals NHS Foundation Trust, Liverpool, UK; ⁵ University of Manchester,
10 Manchester, UK; ⁶ London School of Hygiene and Tropical Medicine, London, UK; ⁷ Centre
11 for Public Health, Queen's University Belfast, Belfast, UK. ⁸ Weill Cornell Medicine-Qatar,
12 Doha, Qatar.

13 **Corresponding author:** Dr Varo Kirthi, Department of Ophthalmology, Faculty of Life
14 Sciences and Medicine, Normanby Building, King's College Hospital, London SE5 9RS
15 United Kingdom. Telephone: +44 (0)20 3299 7791. Email: v.kirthi@nhs.net.

16 **KEY WORDS**

17 Prediabetes, impaired fasting glucose, impaired glucose tolerance, retinopathy, prevalence,
18 epidemiology

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ABSTRACT

Diabetic retinopathy is a leading cause of vision loss globally. The current diagnostic thresholds for diabetes are still based on historic data correlating glycaemic parameters with retinopathy; ~~h~~. However, an excess prevalence of retinopathy has also been reported in prediabetes. ~~This systematic review~~We aimed to determine the reported prevalence of retinopathy in adults with prediabetes. We performed searches using MEDLINE, EMBASE, PubMed, Web of Science, CINAHL, Google Scholar and the Cochrane databases from inception to 1 August 2020. We evaluated methodological quality and certainty of the evidence using a validated risk of bias tool and GRADE, respectively. Twenty-four studies (8759 participants with prediabetes) were included after screening 5994 abstracts and reviewing 98 full-text records. Nineteen studies (79%) reported population-based data. Retinopathy prevalence estimates ranged between 0.3-14.1% (median 7.1%, interquartile range 2.4-10.0%), with high variance in estimates due to differing screening methods, retinopathy grading protocols and study populations. We judged this as low-certainty evidence using GRADE, downgrading for risk of bias and inconsistency. From studies that compared both populations, *post hoc* analysis revealed a lower median retinopathy prevalence in normal glucose tolerance (3.2%, interquartile range 0.3-7.3%) than prediabetes (6.6%, interquartile range 1.9-9.8%). These data suggest an excess prevalence of retinopathy in prediabetes.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1. INTRODUCTION

Prediabetes is defined as suboptimal glycaemia ~~which that~~ does not reach the threshold for type 2 diabetes ^{1,4}. Worldwide, approximately one in 13 adults (374 million) aged 20-79 years have prediabetes, and the vast majority are unaware of the diagnosis ²³. There is a significant predicted burden, with the International Diabetes Federation projecting 587 million people (8.3% of adults) to have prediabetes by 2045 ²³.

The World Health Organization (WHO) uses two specific parameters to define prediabetes: (i) impaired fasting glucose (IFG), defined as a fasting plasma glucose (FPG) of 6.1-6.9 mmol/L (110-125 mg/dL) and (ii) impaired glucose tolerance (IGT), defined as a two-hour plasma glucose of 7.8-11.0 mmol/L (140-200 mg/dL) after ingestion of 75g oral glucose, or a combination of the two based on a two-hour oral glucose tolerance test (OGTT) ¹. The American Diabetes Association (ADA) uses the same cut-off value for IGT (140-200 mg/dL), but has a lower cut-off value for IFG (100-125 mg/dL) ⁴. In addition, the ADA includes a haemoglobin A1c (HbA1c) level of 5.7-6.4% to define prediabetes ⁴.

Current diagnostic thresholds for fasting and two-hour post-load plasma glucose levels are based on the presence of retinopathy reported in population-based studies in Pima Indians, Egypt, and the United States; ~~h-~~ However, subsequent studies have failed to confirm these thresholds, attributed to broad definitions of retinopathy and limited statistical power ^{52,61}. The DETECT-2 study showed that diabetic retinopathy (DR) was associated with a fasting plasma glucose of 6.5 mmol/l ¹⁰. Data also suggest that end-organ complications occur prior to the onset of type 2 diabetes ⁵⁰. Compared to individuals with normal glucose tolerance (NGT), those with prediabetes have an increased prevalence of microvascular disease, elevated all-cause mortality, and a doubling of coronary heart disease mortality ^{51,57}. People with

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

prediabetes and concomitant microvascular disease are also more likely to develop type 2 diabetes^{5,30,58}.

In people with diabetes, the worldwide prevalence of any DR, proliferative DR, diabetic macular edema and vision-threatening DR is 34.6%, 7.0%, 6.8% and 10.2%, respectively⁶³. Hence the early diagnosis of sight-threatening disease is key^{38,50}. Although approaches to population-based screening vary by country, digital retinal photography is considered the most effective screening method for DR⁶². Although isolated retinopathy occurs with increasing age and hypertension, the prevalence varies between 2.6-8.6% even in individuals without diabetes or hypertension, which may be attributed to prediabetes^{39,60}. We aimed to determine and discuss the prevalence of retinopathy in prediabetes by undertaking a systematic review of published data, using evidence-based Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2. RESULTS

2.1 Study characteristics: After removal of duplicate entries, we identified 5155 records from the electronic database searches and selected 98 records for full-text review. Of these, 24 studies (8759 participants with prediabetes) were included in the final review. Reasons for exclusion after full-text review are shown in Figure 1.

Characteristics of the included studies are presented in Table 1. Of the 15 studies that reported age data, 11 reported a mean or median age of participants. Among the 21 studies that reported gender data, gender ratios varied widely from 17.9% to 67.8% male.

Studies were conducted in 22 different countries and ~~6 six~~ WHO regions. Eight studies were conducted in Europe, ~~6 six~~ in the Americas (USA), six in the Western Pacific (China, Japan, Singapore, Australia and Samoa), and 1 each ~~one~~ in South-East Asia (Bangladesh), ~~one in~~ Africa (Mauritius) and ~~one in~~ the Eastern Mediterranean (Egypt). One publication was a multinational study conducted across ~~9 nine~~ countries¹⁶. Thirteen studies reported race or ethnicity data, from a wide variety of backgrounds; ~~2 two~~ studies exclusively examined African Americans and Pima Indians, both from the USA^{35,43}. The majority of studies were cross-sectional and population-based (19/24, 79%); three were cross-sectional, hospital-based studies and two were double-blind, randomised-controlled trials reporting baseline prevalence data. Sample sizes for the included studies varied between 34 and 960. Fifteen studies used WHO criteria to define prediabetes; ~~5~~ five used ADA criteria, two used non-standard or superseded WHO criteria, ~~1 one~~ failed to report how prediabetes was defined, and ~~1 one~~ study used stricter non-standard IFG criteria⁵⁴.

2.2 Risk of bias assessment: Points scored on individual risk of bias items and the overall scores of the included studies are provided in Table S1. We deemed the majority of studies

1
2
3
4
5
6
7 95 (19/24, 79%) 'low' risk whilst the remaining five were deemed 'moderate' risk. The most
8
9 96 common issues were: (i) the likelihood of non-response bias due to a response rate <75% (17
10
11 97 studies); (ii) the study instrument not shown to have reliability or validity, scored for any study
12
13 98 that failed to perform pharmacological mydriasis (14 studies) and (iii) a lack of census or some
14
15 99 form of random selection performed to select the sample (9 studies).

16
17
18 100 ~~Due-Owing~~ to variations in study populations, fields captured on retinal photography,
19
20 101 retinopathy classifications, use of pharmacological dilation and diagnostic methods for
21 102 prediabetes, we considered clinical and statistical (I^2 : 93%) heterogeneity too high to perform
22
23 103 a meta-analysis²⁰. Where quantitative data were available, we recorded median estimates and
24
25 104 ranges. Where such data were lacking, we conducted a narrative analysis of the data.

26
27
28 105 **2.3 Primary outcome:** A summary of the prevalence data is shown in Figure 2 and Table 2.
29
30 106 The median estimated prevalence of retinopathy in prediabetes was 7.1% (interquartile range
31
32 107 (IQR): 2.4-9.7%); ~~h-~~ However, prevalence estimates varied widely, from 0.3% in a study from
33
34 108 the Netherlands (n=478), to 14.1% in a study from Japan (n=303)^{19,26}. The median sample size
35 109 for the at-risk population with prediabetes was 235 (range 34-960).

36
37
38 110 **2.4 GRADE assessment of primary outcome:** Confidence in the body of evidence for the
39
40 111 primary outcome was assessed using the five Grading of Recommendations Assessment,
41
42 112 Development and Evaluation (GRADE) domains: (i) risk of bias, (ii) inconsistency, (iii)
43
44 113 imprecision, (iv) indirectness and (v) publication bias, summarised in Table S2. Although the
45
46 114 overall risk of bias in most studies was low, the majority of studies were at risk of non-response
47
48 115 bias and a significant proportion reported non-random sampling methods. There was also
49
50 116 evidence of inconsistency due to a wide variation in prevalence estimates, which did not
51 117 correlate with study settings. Although 95% confidence intervals for most prevalence estimates

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

were wide, given the total number of participants, if data were pooled the overall estimate of prevalence may be reasonably precise. As the majority of studies were population-based and all studies measured the outcome of interest, we found no evidence of indirectness. Although studies of varying sample sizes reported high and low prevalence estimates, we found no evidence of publication bias. We deemed the overall GRADE assessment of the prevalence of retinopathy in prediabetes low certainty, downgrading one level for risk of bias and one level for inconsistency.

2.5 Subgroup analyses of primary outcome: Where quantitative subgroup data were lacking, we conducted a narrative analysis. As insufficient data were reported, we did not perform an analysis of the time since diagnosis of prediabetes on the prevalence of retinopathy.

2.5.1 WHO region: Median retinopathy estimates by WHO region were 7.6% (range: 1.4-12.0%) for the Americas, 8.9% (range: 0.3-11.0%) for Europe and 6.8% (range: 1.4-14.1%) for the Western Pacific. Only ~~one~~ 1 study contributed to the retinopathy estimates for Africa (9.1%), South-East Asia (13.0%), and the Eastern Mediterranean (1.9%).

2.5.2 Age, gender and ethnicity: Two studies reported age-specific prevalence estimates in prediabetes. Klein and coworkers, et al. recruited participants aged ≥ 55 years and found no increase in retinopathy prevalence with age. ~~However,~~ Herman and coworkers, however, et al. reported a higher prevalence of retinopathy in those aged ≥ 45 years compared to those aged 20-44 years. One study reported a higher prevalence of retinopathy (Wisconsin grade ≥ 15) in females (2.0%) compared to males (0.5%)²⁸. Similarly, only 1 ~~one~~ study compared ethnicity-specific prevalence estimates, with higher rates reported in Hispanic White (10.0%) and non-Hispanic Black (11.6%) individuals, compared to non-Hispanic White individuals (7.5%)⁷.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

The highest estimated prevalence of retinopathy (14.1%) was reported in a Japanese population²⁶.

2.5.3 Subtype of prediabetes: Twelve studies presented prevalence estimates for IGT, with a median prevalence of 7.6% (range: 1.9-12.0%). For IFG, the median prevalence of retinopathy was 10.4% (range: 4.3-14%) based on three studies. One study defined the upper limit of IFG as <6.1 mmol/l, compared to ADA and WHO criteria (<7.0 mmol/l)⁵⁴. Three studies reported prevalence estimates for participants with combined IFG/IGT, with a median prevalence of 8.7% (range: 0.3-9.5%). Seven studies reported prevalence estimates for retinopathy amongst participants with IFG or IGT, with a median prevalence of 6.9% (range: 1.4-14.1%).

2.5.4 Grade of retinopathy: Penman ~~and coworkers et al.~~ reported the prevalence of retinopathy by Early Treatment Diabetic Retinopathy Study (ETDRS) grade⁴³. Of 266 participants with IGT, the number with retinopathy at ETDRS grades 15, 20 and 35 were 12 (4.5%), 9 (3.4%) and 4 (1.5%), respectively. The remaining participants (n=240, 90.2%) had retinopathy at ETDRS grade ≤14. Collins ~~et al. and coworkers~~ (n=97) ~~found reported~~ one case of proliferative retinopathy in a Samoan population, while ~~st~~ Dowse ~~and coworkers et al.~~ (n=165) did not ~~observe report~~ any cases among a mixed population of Indian, Creole and Chinese participants^{11,14}.

2.5.5 Comorbid ocular pathology: Van Leiden ~~and coworkers et al.~~ (n=165) reported a 6% prevalence of hard exudates among participants with IGT³¹. Sundling ~~and coworkers et al.~~ (n=38) ~~had reported 1 one~~ participant (2.6%) with hypertensive retinopathy among those with IGT⁴⁹. There was no difference in the prevalence of glaucoma or age-related macular degeneration in IGT compared to diabetes and NGT. Only ~~1 one~~ study reported the incidence

Formatted: Font: Not Italic
Formatted: Font: Not Italic

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

of pseudophakia (4.9%), hence the prevalence of cataract in phakic eyes could not be reliably determined ²⁹.

2.5.6 Comorbid cardiovascular risk factors: Metabolic data from the included studies are summarized in Table S3. Six studies reported a median prevalence of 59% (range: 31-73%) for hypertension in prediabetes. Subgroup analysis was not possible ~~due~~-owing to a lack of reporting of prevalence estimates stratified by blood pressure.

2.5.7 Method or criteria used to diagnose prediabetes: The median prevalence estimate was higher among the 15 studies that used WHO criteria (9.1%, range: 0.3-14.1%) compared to five studies that used ADA criteria (2.5%, range: 1.4-8.1%). Data on HbA1c were most commonly available (12 studies), followed by fasting plasma glucose (FPG; 9 studies) and OGTT (9 studies), as summarised in Table S2; subgroup analysis was precluded by a lack of detail on the exact test used to diagnose prediabetes. Three studies using HbA1c criteria alone for the diagnosis of prediabetes reported a median prevalence estimate of 8.1% (range: 6.6-9.7%).

2.5.8 Method used to diagnose retinopathy: All included studies diagnosed retinopathy on retinal photography, but with a range of methods, from 1-field to 7-field fundus imaging. Ten studies that used pharmacological mydriasis reported the highest median prevalence of retinopathy (9.5%, range: 1.9-13.0%), compared to ~~5~~ five studies that performed non-mydriatic imaging (6.9%, range: 1.9-14.1%) and ~~5~~ five studies that obtained images after dark adaptation i.e. physiological mydriasis (2.0%, range: 1.4-8.1%). The remaining studies failed to provide sufficient information on mydriasis status.

2.6 Secondary outcomes: None of the included studies ~~found reported~~ any microvascular abnormalities that ~~were~~ are not standard features of diabetic retinopathy. Only ~~3~~ three studies

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

reported the prevalence of maculopathy in prediabetes, based solely on retinal photography. Lamparter ~~and coworkers et al.~~ (n=922) and Pang ~~and coworkers et al.~~ (n=865) ~~determined~~ reported the prevalence of clinically significant macular edema (CSMO) as 0.2% and 2.4%, respectively ^{29,42}. By contrast Penman ~~and coworkers et al. reported~~ had no cases of maculopathy ⁴³.

2.7 Post hoc analysis: Data for all study groups ~~are~~ summarised in Tables S4 and S5. To explore if there is an excess prevalence of retinopathy in prediabetes compared to NGT, we performed an exploratory *post hoc* comparison. Seventeen of the 24 studies also reported prevalence estimates of retinopathy in NGT. From these studies, the median estimated prevalence of retinopathy in prediabetes (6.6%, IQR: 1.9-9.8%) was higher than in NGT (3.2%, IQR: 0.3-7.3%), summarised in Figure S1. Prevalence estimates and sample sizes however varied widely in NGT (0.1-10.3% and 29 to 3970 participants respectively). The majority (13/17 studies, 76%) reported a higher prevalence estimate in prediabetes than NGT.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

3. DISCUSSION

3.1 Summary of retinopathy outcomes: In this systematic review, we found the median prevalence of retinopathy in prediabetes to be 7.1% (IQR: 2.4-9.7%), with the majority of studies (15/24, 62.5%) reporting a prevalence of $\geq 5\%$ in prediabetes. ~~However, T~~there was, ~~however,~~ considerable variation in prevalence estimates (0.3-14.1%), particularly between studies that used pharmacological and physiological mydriasis. Despite this variation, on *post hoc* analysis we found a higher median prevalence of retinopathy in prediabetes (6.6%) than NGT (3.2%) within the same studies. We also found a low prevalence of more-than-mild retinopathy or CSMO in prediabetes, although data were limited.

3.2 Comparisons with previous data: A comparison of retinopathy prevalence estimates between studies was challenging given the varying definitions of dysglycaemia, retinopathy, the influence of hypertension, retinal imaging modalities, study populations and designs^{39,45,50}. Clinical heterogeneity may in part explain the ~~considerable notable~~ variations in prevalence estimates. Indeed, the level of statistical heterogeneity (I^2 : 93%) was also high, thus a summary estimate of pooled prevalence was not feasible. Overall, the reported excess of retinopathy in prediabetes is in keeping with other retinal and systemic microvascular changes. Microaneurysms, a well characterised DR lesion, occur in 6.9% of participants with impaired glucose metabolism¹³. Isolated retinal lesions occur in 2.6-8.6% of people without diabetes or hypertension, suggesting that dysglycaemia is an important risk factor for the development of retinal vascular changes³⁹. Reported associations between prediabetes and peripheral neuropathy, nephropathy and cardiac autonomic neuropathy provide further evidence of multisystem end-organ dysfunction preceding the onset of type 2 diabetes^{15,48,50}.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

3.3 Demographic risk factors: Risk factors for DR include age, ethnicity, disease duration, and the severity of hyperglycaemia⁶³. The mean ages of participants were similar to those reported in populations with DR⁶³. A paucity of age-specific retinopathy estimates limited comparisons with prior studies. Only ~~one~~ study reported a higher prevalence of retinopathy in females, despite reports of retinopathy being more prevalent in males, with or without diabetes^{6,41}. One study reported a higher prevalence of retinopathy among non-Hispanic Black participants, similar to data for individuals with diabetes⁶³.

3.4 HbA1c and comparisons between IFG and IGT: Estimates for retinopathy varied for IFG, IGT and combined IFG/IGT subgroups, but only ~~two~~ studies reported data for all ~~three~~ subgroups. Although people with combined IFG/IGT are at higher risk of progressing to diabetes (15-19%) compared to isolated IFG (6-9%) or IGT (4-6%), this was not reflected in the retinopathy prevalence estimates reported⁵⁰. Despite using a narrow range of ≥ 5.6 and < 6.1 mmol/L for IFG, Tyrberg ~~and coworkers et al. reported- found~~ a retinopathy prevalence of 10.4%⁵⁴. Different pathological mechanisms have been postulated in IFG and IGT, based on the origin of insulin resistance reported as predominantly hepatic and muscular, respectively^{36,50}. This may explain the differences in retinopathy prevalence. HbA1c provides an indication of chronic glycaemia, whereas the OGTT measures glycaemia at a single time point. Importantly, HbA1c has a similar relationship to OGTT (fasting and 2-hour plasma glucose), as demonstrated by DETECT-2¹⁰. Using HbA1c diagnostic criteria (5.7%-6.4%) alone, annual diabetes incidence rates are broadly similar in IFG and IGT (7%)⁵⁰.

3.5 Retinopathy severity: Prediabetes was predominantly associated with early stage retinopathy using ETDRS grades, and the most commonly reported retinal lesions were microaneurysms¹³. Only ~~two~~ studies (n=262) reported the prevalence of proliferative diabetic retinopathy in prediabetes, with ~~one~~ affected participant. Similar to diabetes, the risk

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

of microvascular dysfunction ~~has been reported to~~ increase with the duration of prediabetes⁴⁴.

3.6 Retinal imaging methods: Pharmacological mydriasis considerably improves the efficacy of DR screening, with a much lower poor-quality image rate than non-mydriatic fundal imaging (3.7% compared to 19.7%, respectively)⁴⁵. In our analysis, a higher median prevalence of retinopathy was observed after pharmacological mydriasis compared to both no mydriasis and physiological mydriasis. Furthermore, studies that did not use pharmacological mydriasis were given a higher risk of bias score under the ‘study instrument reliability and validity’ domain. The number of retinal fields imaged also varied ~~between~~ among studies, which may have affected retinopathy estimates; however, there is an 87% agreement between two- and seven-field (gold-standard) imaging for the detection of any retinopathy³⁴. While ~~est~~ seven-field imaging correlates well with clinical examination by an ophthalmologist, the technical failure rate is higher compared to two-field imaging and ungradable images affect retinopathy detection rates⁴⁶.

3.7 Comorbid ocular and metabolic disease: Data on comorbid ocular diseases were limited. ~~W~~where reported, cataract data were presented without lens status (phakic or pseudophakic). Hypertension and other metabolic syndrome components, including dyslipidaemia and body mass index (BMI), were higher in prediabetes than NGT. While ~~est~~ the dynamic relationship between glycaemic control and retinal damage are well documented, hypertension is an important ~~co~~-contributor to retinopathy^{12,55,56}. Animal models and human studies suggest that retinal arteriolar endothelial dysfunction and chronic inflammation are common pathological processes underlying both DR and hypertensive retinopathy^{22,39}. ~~h~~However, data on hypertension-specific retinopathy rates in prediabetes were limited. Dyslipidaemia in prediabetes is characterised by low high-density lipoprotein (HDL) and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


raised triglycerides (TG) ^{8,25}. One study reported a significantly higher prevalence of metabolic syndrome in severely obese prediabetic participants compared to NGT ¹⁷. Given the high prevalence of metabolic syndrome components in this population, it was unsurprising to note several studies reporting associations with microalbuminuria. The association between retinopathy and dyslipidaemia is more variable, with associations reported between hypercholesterolaemia and retinopathy lesions (hard exudates) and also between hypertriglyceridaemia and the risk of DR ^{9,33}.

3.8 Limitations of the current data: Only ~~7~~seven studies (29%) had more than 500 participants with six studies (25%) having fewer than 100 participants. Small studies are at risk of reporting bias and prevalence estimates may be less reliable. Prediabetes tests and diagnostic criteria differed between studies with prevalence data on IFG, IGT and combined subgroups from the same participants were provided in only two studies. ~~Due to~~Because of a high level of clinical heterogeneity from the variety of diagnostic approaches, and statistical heterogeneity from variations in study design and methods, we did not perform a meta-analysis; h-~~h-~~However, where comparisons were made with NGT within the same study, the majority reported higher prevalence estimates in prediabetes than in NGT.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

4. CONCLUSIONS

There is an increased prevalence of retinopathy in individuals with prediabetes (median: 7.1%) compared with those with normal glucose tolerance. The current gluco-centric thresholds for diabetes fail to capture this burden of subclinical end-organ damage, which affects a sizeable minority of people with prediabetes. With an estimated 10% annual incidence of progression to diabetes and growing evidence of early multisystem involvement ⁵⁰, greater vigilance may be needed to both monitor and mitigate end-organ damage in prediabetes.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

5. METHOD OF LITERATURE SEARCH STATEMENT

5.1 Search strategy: This systematic review was registered with PROSPERO (CRD: 42020184820) and conducted using PRISMA guidelines as per a published protocol ^{27,47}. Comprehensive electronic literature searches were conducted in MEDLINE (via OVID), EMBASE (via OVID), Web of Science, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Google Scholar and the Cochrane databases, from inception to 1 August 2020. The search strategies were independently reviewed by an expert information specialist using the Peer Review of Electronic Search Strategies (PRESS) checklist ³². The MEDLINE search strategy is included as an example (Appendix S1). References of included studies and review articles identified during the course of the searches were used to identify any additional articles. Results from the database searches were merged using an electronic reference manager (Rayyan, Qatar Computing Research Institute, Qatar) to facilitate the removal of duplicate articles ⁴⁰.

5.2 Eligibility criteria: Inclusion criteria were adults aged 18 years or older with prediabetes defined by WHO or ADA criteria ^{1,4}. This included IFG, IGT and combined IFG/IGT as prediabetes subgroups. Population-based cohort or cross-sectional studies from any country in any setting were considered, provided a full-text original manuscript or translation was available in English. Studies were required to report retinopathy prevalence detected on retinal photography, with or without pharmacological mydriasis, using either 1-, 2-, 3- or 7-field colour imaging. A lack of detail on the method used or quality of images taken, or a lack of reporting of the definition of prediabetes or retinopathy were noted, but not considered reasons for exclusion.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

5.3 Outcomes: The primary outcome was the prevalence of any diabetes-specific retinopathy on retinal photography in prediabetes, as per International Clinical Diabetic Retinopathy Severity Scale (ICDRSS) classification ⁵⁹. This was defined by the presence of at least one of the following features on retinal photography:

- (i) Microaneurysms
- (ii) Intraretinal haemorrhages
- (iii) Hard exudates
- (iv) Cotton-wool spots
- (v) Venous beading
- (vi) Intraretinal microvascular abnormalities (IRMAs)
- (vii) New vessels at the optic disc (NVD) or elsewhere (NVE)
- (viii) Vitreous or pre-retinal haemorrhage

Secondary outcomes were the prevalence of: (i) any retinal microvascular abnormalities on retinal photography that are not standard features of diabetic retinopathy as per ICDRSS classification, and (ii) any maculopathy on retinal photography in prediabetes.

Where available, data on additional imaging, such as fundus fluorescein angiography (FFA) or optical coherence tomography (OCT), were extracted if reported. Data on the method of diagnosing prediabetes and cardiovascular and metabolic parameters were extracted. Metabolic syndrome was defined as per consensus criteria from the WHO, National Cholesterol Education Program Adult Treatment Panel III and ADA ^{1-3,37,64}.

5.4 Study selection and data collection: Two reviewers independently screened titles and abstracts, excluding any that did not satisfy the eligibility criteria. Disagreements were resolved by discussion, and via third (senior) reviewer arbitration. Articles of interest were selected for

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

full-text assessment; if there was any doubt regarding eligibility, the full-text article was retrieved. Two reviewers independently assessed full-text articles against the eligibility criteria. A PRISMA flowchart is included in Figure 1. Two reviewers independently extracted data using pre-piloted forms. Where reported, secondary outcome data including: (i) the definition and prevalence of non-standard retinopathy features and (ii) the definition and prevalence of maculopathy features, were recorded. Prevalence estimates for co-morbid ocular pathology (e.g., cataract) and cardiovascular risk factors (e.g., hypertension, metabolic syndrome) were also recorded.


5.5 Risk of bias assessment: All eligible studies were assessed using a modified critical appraisal tool (Appendix S2). The tool features nine questions, each scoring 0 or 1, to assess selection, non-response, measurement and data analysis biases ²¹. Quality assessment was conducted by two reviewers independently, with disagreements resolved by discussion. Judgments on the overall risk of bias were based on the total score for each article: 0-3 considered 'low', 4-6 considered 'moderate' and ≥ 7 considered 'high risk', based on the reviewers' subjective judgment of the preceding nine items ²¹.

5.6 Data analysis: Data were analysed using Review Manager 5 (The Cochrane Collaboration, Copenhagen, Denmark) and Microsoft Excel 2016 (Microsoft, Redmond, USA). Heterogeneity between included studies was assessed on study design, populations and methods used to measure outcomes. Statistical heterogeneity was assessed using the I^2 statistic and by visual inspection of forest plots ²⁰. Subgroup analyses of the primary outcome were conducted on the following covariates: (i) WHO region; (ii) age, gender, ethnicity; (iii) time since diagnosis of prediabetes; (iv) subtype of prediabetes (e.g., IGT); (v) grade of retinopathy; (vi) comorbid ocular pathology (e.g., cataract); (vii) comorbid cardiovascular risk factors (e.g., hypertension);

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

(viii) method or criteria used to diagnose prediabetes and (ix) method used to diagnose retinopathy.

5.7 Grading of evidence: The certainty of the evidence was assessed using the GRADE approach, detailed in Table S1 ^{18,24}.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

KEY REFERENCES

11. Colagiuri S, Lee CMY, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K, et al. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care. 2011 Jan 1;34(1):145–50.

The DETECT-2 study, which suggested that the fasting plasma glucose threshold for type 2 diabetes could be lowered to 6.5 mmol/l based on the presence of diabetes-specific retinopathy.

25. International Diabetes Federation. International Diabetes Federation Atlas (9th Edition). 2019 [cited 2020 May 1]; Available from: <https://www.diabetesatlas.org/>

The IDF Atlas provides an up-to-date global perspective of diabetes and prediabetes.

29. Kirthi V, Nderitu P, Alam U, Evans J, Nevitt S, Malik RA, et al. Prevalence of retinopathy in prediabetes: protocol for a systematic review and meta-analysis. BMJ Open. 2021 Jan 7;11(1):e040997.

The peer-reviewed protocol for this systematic review.

HIGHLIGHTS

- This systematic review found the prevalence of retinopathy in prediabetes was 7.1%.
- This represents an excess prevalence versus those with normoglycaemia.
- Hyperglycaemia can cause retinal damage prior to the diagnosis of diabetes.

CONTRIBUTION STATEMENT

All authors meet the ICMJE uniform requirements for authorship. VK, JE, UA, RAM and TLJ conceived the topic of this systematic review. VK and PN designed the search strategies, reviewed by an expert information specialist (IG), JE and SN. VK and PN performed the searches, data collection and data extraction with senior oversight from UA, JE and SN. SN provided statistical oversight of the data analysis. All authors were involved in the drafting, revision and final approval of the article to be published.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ACKNOWLEDGEMENTS

We are grateful to Iris Gordon, Information Specialist for the Cochrane Eyes and Vision Group, for her independent appraisal of the search strategies performed in this systematic review.

FUNDING

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

DECLARATION OF INTEREST

The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article.

DATA AVAILABILITY

All data generated or analysed during this study are included in this published article and its accompanying electronic supplementary material file.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

REFERENCES

1. Alberti K, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med J Br Diabet Assoc.* 1998;15(7):539-553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
2. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation.* 2009;120(16):1640-1645. doi:10.1161/CIRCULATIONAHA.109.192644
3. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. *Diabetes Care.* 2018;41(Suppl 1):S13-S27. doi:10.2337/dc18-S002
4. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care.* 2010;33(Suppl 1):S62-S69. doi:10.2337/dc10-S062
5. Azmi S, Ferdousi M, Petropoulos IN, et al. Corneal confocal microscopy identifies small-fiber neuropathy in subjects with impaired glucose tolerance who develop type 2 diabetes. *Diabetes Care.* 2015;38(8):1502-1508. doi:10.2337/dc14-2733
6. Bertelsen G, Peto T, Lindekleiv H, et al. Sex differences in risk factors for retinopathy in non-diabetic men and women: the Tromsø Eye Study. *Acta Ophthalmol (Copenh).* 2014;92(4):316-322. doi:10.1111/aos.12199
7. Bower JK, Brancati FL, Selvin E. No ethnic differences in the association of glycosylated hemoglobin with retinopathy: the national health and nutrition examination survey 2005-2008. *Diabetes Care.* 2013;36(3):569-573. doi:10.2337/dc12-0404
8. Chakarova N, Tankova T, Atanassova I, Dakovska L. Serum lipid and hsCRP levels in prediabetes--impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). *Diabetes Res Clin Pract.* 2009;86(1):56-60. doi:10.1016/j.diabres.2009.04.005
9. Chew EY, Klein ML, Ferris FL, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. *Arch Ophthalmol Chic Ill 1960.* 1996;114(9):1079-1084. doi:10.1001/archoph.1996.01100140281004
10. Colagiuri S, Lee CMY, Wong TY, et al. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. *Diabetes Care.* 2011;34(1):145-150. doi:10.2337/dc10-1206
11. Collins VR, Dowse GK, Plehwe WE, et al. High prevalence of diabetic retinopathy and nephropathy in Polynesians of Western Samoa. *Diabetes Care.* 1995;18(8):1140-1149. doi:10.2337/diacare.18.8.1140
12. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med.* 1993;329(14):977-986. doi:10.1056/NEJM199309303291401

13. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. *Diabet Med J Br Diabet Assoc.* 2007;24(2):137-144. doi:10.1111/j.1464-5491.2007.02043.x

14. Dowse GK, Humphrey AR, Collins VR, et al. Prevalence and risk factors for diabetic retinopathy in the multiethnic population of Mauritius. *Am J Epidemiol.* 1998;147(5):448-457. doi:10.1093/oxfordjournals.aje.a009470

15. Eleftheriadou A, Williams S, Nevitt S, et al. The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review. *Diabetologia.* 2020;(in press).

16. Gabriel R, Boukichou Abdelkader N, Acosta T, et al. Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data. *PloS One.* 2020;15(4):e0231196. doi:10.1371/journal.pone.0231196

17. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. *J Am Coll Cardiol.* 2012;59(7):635-643. doi:10.1016/j.jacc.2011.08.080

18. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ.* 2008;336(7650):924-926. doi:10.1136/bmj.39489.470347.AD

19. Hanssen NMJ, Scheijen JLJM, Houben AJHM, et al. Fasting and post-oral-glucose-load levels of methylglyoxal are associated with microvascular, but not macrovascular, disease in individuals with and without (pre)diabetes: The Maastricht Study. *Diabetes Metab.* Published online February 10, 2020. doi:10.1016/j.diabet.2020.02.002

20. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003;327(7414):557-560. doi:10.1136/bmj.327.7414.557

21. Hoy D, Brooks P, Woolf A, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. *J Clin Epidemiol.* 2012;65(9):934-939. doi:10.1016/j.jclinepi.2011.11.014

22. Huang Z, Chen C, Li S, Kong F, Shan P, Huang W. Serum markers of endothelial dysfunction and inflammation increase in hypertension with prediabetes mellitus. *Genet Test Mol Biomark.* 2016;20(6):322-327. doi:10.1089/gtmb.2015.0255

23. International Diabetes Federation. International Diabetes Federation Atlas (9th Edition). Published online 2019. Accessed May 1, 2020. <https://www.diabetesatlas.org/>

24. Iorio A, Spencer FA, Falavigna M, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. *BMJ.* 2015;350:h870. doi:10.1136/bmj.h870

25. Kansal S, Kamble TK. Lipid Profile in Prediabetes. *J Assoc Physicians India.* 2016;64(3):18-21.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

26. Kawasaki R, Wang JJ, Rochtchina E, et al. Cardiovascular risk factors and retinal microvascular signs in an adult Japanese population: the Funagata Study. *Ophthalmology*. 2006;113(8):1378-1384. doi:10.1016/j.ophtha.2006.02.052

27. Kirthi V, Nderitu P, Alam U, et al. Prevalence of retinopathy in prediabetes: protocol for a systematic review and meta-analysis. *BMJ Open*. 2021;11(1):e040997. doi:10.1136/bmjopen-2020-040997

28. Klein R, Barrett-Connor EL, Blunt BA, Wingard DL. Visual impairment and retinopathy in people with normal glucose tolerance, impaired glucose tolerance, and newly diagnosed NIDDM. *Diabetes Care*. 1991;14(10):914-918. doi:10.2337/diacare.14.10.914

29. Lamparter J, Raum P, Pfeiffer N, et al. Prevalence and associations of diabetic retinopathy in a large cohort of prediabetic subjects: the Gutenberg Health Study. *J Diabetes Complications*. 2014;28(4):482-487. doi:10.1016/j.jdiacomp.2014.02.008

30. Lee CC, Perkins BA, Kayaniyl S, et al. Peripheral neuropathy and nerve dysfunction in individuals at high risk for type 2 diabetes: The PROMISE Cohort. *Diabetes Care*. 2015;38(5):793-800. doi:10.2337/dc14-2585

31. van Leiden HA, Dekker JM, Moll AC, et al. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study. *Diabetes Care*. 2002;25(8):1320-1325. doi:10.2337/diacare.25.8.1320

32. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement. *J Clin Epidemiol*. 2016;75:40-46. doi:10.1016/j.jclinepi.2016.01.021

33. Modjtahedi BS, Bose N, Papakostas TD, Morse L, Vavvas DG, Kishan AU. Lipids and diabetic retinopathy. *Semin Ophthalmol*. 2016;31(1-2):10-18. doi:10.3109/08820538.2015.1114869

34. Moss SE, Meuer SM, Klein R, Hubbard LD, Brothers RJ, Klein BE. Are seven standard photographic fields necessary for classification of diabetic retinopathy? *Invest Ophthalmol Vis Sci*. 1989;30(5):823-828.

35. Nagi DK, Pettitt DJ, Bennett PH, Klein R, Knowler WC. Diabetic retinopathy assessed by fundus photography in Pima Indians with impaired glucose tolerance and NIDDM. *Diabet Med J Br Diabet Assoc*. 1997;14(6):449-456. doi:10.1002/(SICI)1096-9136(199706)14:6<449::AID-DIA367>3.0.CO;2-D

36. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. *Diabetes Care*. 2007;30(3):753-759. doi:10.2337/dc07-9920

37. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106(25):3143-3421.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

38. National Eye Institute. People with diabetes can prevent vision loss. Published online 2019. Accessed August 1, 2020. <https://www.nei.nih.gov/sites/default/files/2019-06/diabetes-prevent-vision-loss.pdf>

39. Nguyen TT, Wang JJ, Wong TY. Retinal vascular changes in pre-diabetes and prehypertension: new findings and their research and clinical implications. *Diabetes Care*. 2007;30(10):2708-2715. doi:10.2337/dc07-0732

40. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan - a web and mobile app for systematic reviews. *Syst Rev*. 2016;(5):210. doi:10.1186/s13643-016-0384-4

41. Ozawa GY, Bearse MA, Adams AJ. Male-female differences in diabetic retinopathy? *Curr Eye Res*. 2015;40(2):234-246. doi:10.3109/02713683.2014.958500

42. Pang C, Jia L, Jiang S, et al. Determination of diabetic retinopathy prevalence and associated risk factors in Chinese diabetic and pre-diabetic subjects: Shanghai diabetic complications study. *Diabetes Metab Res Rev*. 2012;28(3):276-283. doi:10.1002/dmrr.1307

43. Penman A, Hoadley S, Wilson JG, Taylor HA, Chen CJ, Sobrin L. P-selectin plasma levels and genetic variant associated with diabetic retinopathy in African Americans. *Am J Ophthalmol*. 2015;159(6):1152-1160.e2. doi:10.1016/j.ajo.2015.03.008

44. Reis JP, Allen NB, Bancks MP, et al. Duration of diabetes and prediabetes during adulthood and subclinical atherosclerosis and cardiac dysfunction in middle age: the CARDIA study. *Diabetes Care*. 2018;41(4):731-738. doi:10.2337/dc17-2233

45. Scanlon PH. The English National Screening Programme for diabetic retinopathy 2003-2016. *Acta Diabetol*. 2017;54(6):515-525. doi:10.1007/s00592-017-0974-1

46. Scanlon PH, Malhotra R, Greenwood RH, et al. Comparison of two reference standards in validating two field mydriatic digital photography as a method of screening for diabetic retinopathy. *Br J Ophthalmol*. 2003;87(10):1258-1263. doi:10.1136/bjo.87.10.1258

47. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2015;350:g7647. doi:10.1136/bmj.g7647

48. Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. *The Neurologist*. 2008;14(1):23-29. doi:10.1097/NRL.0b013e31815a3956

49. Sundling V, Platou CGP, Jansson RW, Bertelsen G, Wølle E, Gulbrandsen P. Retinopathy and visual impairment in diabetes, impaired glucose tolerance and normal glucose tolerance: the Nord-Trøndelag Health Study (the HUNT study). *Acta Ophthalmol (Copenh)*. 2012;90(3):237-243. doi:10.1111/j.1755-3768.2010.01998.x

50. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. *The Lancet*. 2012;379(9833):2279-2290. doi:10.1016/S0140-6736(12)60283-9

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

555 51. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of
556 glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes:
557 an analysis from the Whitehall II study. *Lancet Lond Engl.* 2009;373(9682):2215-2221.
10558 doi:10.1016/S0140-6736(09)60619-X

559 52. Tapp RJ, Zimmet PZ, Harper CA, et al. Diagnostic thresholds for diabetes: the
13560 association of retinopathy and albuminuria with glycaemia. *Diabetes Res Clin Pract.*
14561 2006;73(3):315-321. doi:10.1016/j.diabres.2006.02.008

562 53. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report
16563 of the Expert Committee on the diagnosis and classification of diabetes mellitus.
17564 *Diabetes Care.* 1997;20(7):1183-1197. doi:10.2337/diacare.20.7.1183

18
1965 54. Tyrberg M, Melander A, Lövestam-Adrian M, Lindblad U. Retinopathy in subjects with
20666 impaired fasting glucose: the NANSY-Eye baseline report. *Diabetes Obes Metab.*
21667 2008;10(8):646-651. doi:10.1111/j.1463-1326.2007.00759.x

22568 55. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared
23569 with conventional treatment and risk of complications in patients with type 2 diabetes
24570 (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet Lond Engl.*
2571 1998;352(9131):837-853.

26
2772 56. UKPDS Group. Tight blood pressure control and risk of macrovascular and
28773 microvascular complications in type 2 diabetes: UKPDS 38. *BMJ.* 1998;317(7160):703-
29774 713. doi:10.1136/bmj.317.7160.703

30575 57. Vistisen D, Witte DR, Brunner EJ, et al. Risk of cardiovascular disease and death in
31576 individuals with prediabetes defined by different criteria: the Whitehall II study.
32577 *Diabetes Care.* 2018;41(4):899-906. doi:10.2337/dc17-2530

33
34578 58. Wagner R, Heni M, Tabák AG, et al. Pathophysiology-based subphenotyping of
3579 individuals at elevated risk for type 2 diabetes. *Nat Med.* Published online January 4,
3680 2021. doi:10.1038/s41591-020-1116-9

37581 59. Wilkinson CP, Ferris FL, Klein RE, et al. Proposed international clinical diabetic
38582 retinopathy and diabetic macular edema disease severity scales. *Ophthalmology.*
39583 2003;110(9):1677-1682. doi:10.1016/S0161-6420(03)00475-5

40
41584 60. Wong TY, Klein R, Sharrett AR, et al. The prevalence and risk factors of retinal
42585 microvascular abnormalities in older persons: The Cardiovascular Health Study.
43586 *Ophthalmology.* 2003;110(4):658-666. doi:10.1016/S0161-6420(02)01931-0


44
4587 61. Wong TY, Liew G, Tapp RJ, et al. Relation between fasting glucose and retinopathy for
46588 diagnosis of diabetes: three population-based cross-sectional studies. *Lancet Lond Engl.*
47589 2008;371(9614):736-743. doi:10.1016/S0140-6736(08)60343-8

48590 62. World Health Organization. Diabetic retinopathy screening: a short guide. Published
49591 online July 2, 2021. Accessed February 1, 2022.
50592 <https://apps.who.int/iris/bitstream/handle/10665/336660/9789289055321-eng.pdf>

51
52593 63. Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of
53594 diabetic retinopathy. *Diabetes Care.* 2012;35(3):556-564. doi:10.2337/dc11-1909

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

64. Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. *Obes Facts*. 2015;8(6):402-424. doi:10.1159/000442721



1
2
3
4
5
6
7
598 **TABLE AND FIGURE LEGENDS**
8
9

10
599 **Table 1. Characteristics of included studies.**
11

12
600 **Footnotes:** C, cohort study; CS, cross-sectional study; HA, Hispanic; HB, hospital-based; IFG, impaired fasting
13 601 glucose; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; NHB, non-Hispanic Black; NHW,
14 602 non-Hispanic White; nT2DM, new or screen-detected type 2 diabetes mellitus; PB, population-based; PD,
15 603 prediabetes; T2DM, known type 2 diabetes mellitus. * data not reported; † aggregate value including other study
16 604 groups (e.g., NGT, T2DM); ‡ mean value ± 95% confidence intervals; § median value with ranges in brackets; **
17 605 prediabetes group defined by HbA1c criteria only.
18
19

20
606 **Table 2. Prevalence of retinopathy in prediabetes from included studies.**
21

22
607 **Footnotes:** ADA, American Diabetes Association; CSMO, clinically-significant macular oedema; DRDSS,
23 608 Diabetic Retinopathy Disease Severity Scale; ETDRS, Early Treatment Diabetic Retinopathy Study; ICDRSS,
24 609 International Clinical Diabetic Retinopathy Severity Scale; HE, hard exudate; IFG, impaired fasting glucose;
25 610 IGT, impaired glucose tolerance; NGT, normal glucose tolerance; NSC, National Screening Committee (UK);
26 611 PD, prediabetes; PDR, proliferative diabetic retinopathy; WES-DR, Wisconsin Epidemiologic Study of Diabetic
27 612 Retinopathy; WHO, World Health Organization. * data not reported; † additional data available for ethnicity-
28 613 specific prevalence figures; ‡ IFG defined as ≥5.6 and <6.1 mmol/l; ** prediabetes group defined by HbA1c
29 614 criteria only.
30
31

32
33
34
615 **Figure 1. PRISMA flowchart of study selection process.**
35

36
616 **Figure 2. Forest plot of the prevalence of retinopathy in prediabetes from included**
37 617 **studies.**
38


39
618 **Footnotes:** * Prediabetes group size estimated from reported retinopathy prevalence and number of affected
40 619 individuals. ** Aggregate prevalence estimates presented for impaired fasting glucose (IFG), impaired glucose
41 620 tolerance (IGT) and combined impaired fasting glucose with impaired glucose tolerance (IFG-IGT), (CI)
42 621 confidence interval. All studies are population-based, except three hospital-based studies (blue highlights) and
43 622 two randomised-controlled trials (green highlights). Box size proportional to precision.
44

45
46
47
623 **Figure 3. Forest plot of the prevalence of retinopathy in prediabetes and normal glucose**
48 624 **tolerance from included studies reporting data for both groups.**
49


50
625 **Footnotes:** Normal glucose tolerance (NGT) prevalence estimates in blue, prediabetes prevalence estimates in
51 626 red. ^a Prediabetes group size estimated from reported retinopathy prevalence and number of affected individuals.
52 627 ^b Impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and combined impaired fasting glucose with
53 628 impaired glucose tolerance (IFG/IGT) retinopathy prevalence estimates aggregated with total prediabetes group
54 629 size used for 95% confidence interval (CI) estimation. ^c NGT group size estimated from the total study sample
55 630 minus the reported prediabetes population. ^d Prediabetes group size estimated from reported retinopathy
56 631 prevalence and number of affected individuals. All studies are population-based, except two hospital-based studies
57 632 (blue highlights). Box size proportional to precision.
58
59
60
61
62
63
64
65

RESPONSE TO REVIEWERS' COMMENTS

Please find attached the final manuscript with some minor tracked changes and also a clean version. No changes have been made to the editorial revisions suggested.

1 **Figure 1. PRISMA flowchart of study selection process**


1 **Figure 2. Forest plot of the prevalence of retinopathy in prediabetes from included studies.**



2

3 **Abbreviations and footnotes:** * Prediabetes group size estimated from reported retinopathy prevalence and number of affected individuals. ** Aggregate prevalence estimates
 4 presented for impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and combined impaired fasting glucose with impaired glucose tolerance (IFG-IGT), (CI)
 5 confidence interval. All studies are population-based, except three hospital-based studies (blue highlights) and two randomised-controlled trials (green highlights). Box size
 6 proportional to precision.

1 **Figure 3. Forest plot of the prevalence of retinopathy in prediabetes and normal glucose tolerance from included studies reporting data**
 2 **for both groups.**



4 **Footnotes:** Normal glucose tolerance (NGT) prevalence estimates in blue, prediabetes prevalence estimates in red. ^aPrediabetes group size estimated from reported retinopathy
5 prevalence and number of affected individuals. ^b Impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and combined impaired fasting glucose with impaired
6 glucose tolerance (IFG/IGT) retinopathy prevalence estimates aggregated with total prediabetes group size used for 95% confidence interval (CI) estimation. ^cNGT group size
7 estimated from the total study sample minus the reported prediabetes population. ^d Prediabetes group size estimated from reported retinopathy prevalence and number of
8 affected individuals. All studies are population-based, except two hospital-based studies (blue highlights). Box size proportional to precision.

1 **Table 1. Characteristics of included studies.**

Author	Country	Study period	Design	Study group(s)	Sample size	Mean age \pm SD, or median age (range)	Male gender (%)	Race or ethnicity
Hanssen (2020)	The Netherlands	2010-2013	PB, C	IFG or IGT	478	61.6 \pm 7.6	54	*
Callaghan (2020)	USA	2015-2018	HB, CS	IFG or IGT	56	44.7 \pm 11.4	17.9	White 78.8% White 69.6% White 87.8%
Gabriel (2020)	Australia, Austria, Bulgaria, Kuwait, Poland, Serbia, Spain and Turkey	Ongoing	RCT	IFG or IGT	809	58.5 \pm 7.6	41.9	*
Sokolowska (2016)	Poland	*	HB, CS	IFG or IGT	61	58	33.3	*
Penman (2015)	USA	2009-2012	HB, CS	IGT	266	65.7 \pm 9.6	40.2	African American
Hu (2015)	China	2006-	PB, CS	IFG or IGT	657	45.6 \pm 1.3 †	35.0	Chinese
Bhargava (2014)	Singapore	*	PB, CS	PD**	829	*	*	Indian
Lamparter (2014)	Germany	2007-2008	PB, C	PD**	922	59.9 \pm 9.1	51.8	*
Akhter (2013)	Bangladesh	*	PB, CS	IFG or IGT	54	*	56 †	Bangladeshi
Bower (2013)	USA	2005-2008	PB, CS	PD**	631	*	*	NHW: 41% NHB: 30% HA: 29%

Dyck (2012)	USA	2000-2005	PB, CS	IFG IGT IFG with IGT	174	64 (22-76) [§]	67.8	*
Sundling (2012)	Norway	2004-2005	PB, CS	IGT	34	57 ± 15	36.8	*
Pang (2011)	China	1996-2007	PB, CS	IGT	865	62.3 ± 10.8	42.9	Chinese
Munch (2011)	Denmark	1991-2001	PB, CS	IFG IGT IFG with IGT	59 152 64	*	*	*
Tyrberg (2008)	Sweden	*	RCT	IFG	154	*	58.4	*
Tikellis (2007)	Australia	1999-2000	PB, CS	IFG or IGT	960	58.9 ± 13.5	43.0	*
Kawasaki (2006)	Japan	2000-2002	PB, CS	IGT	303 [†]	58.6 [†]	42.3 [†]	Japanese
Van Leiden (2002)	The Netherlands	1989-1992	PB, CS	IGT	177	64.2 ± 7.3	51	Caucasian
Herman (1998)	Egypt	*	PB, CS	IGT	103	*	41	*
Rajala (1998)	Finland	1990-1992	PB, CS	IGT	204	*	43.9 [†]	*
Dowse (1998)	Mauritius	1987-1992	PB, CS	IGT	165	*	45.2 [†]	Indian, Creole and Chinese

Nagi (1997)	USA	1982-1990	PB, CS	IGT	288 (incl. NGT) [†]	45 (15-93, incl. NGT) ^{†§}	51.0 (incl. NGT) [†]	Pima Indians
Collins (1995)	Samoa	1978-1991	PB, CS	IGT	97	*	37.2	Samoa
Klein (1991)	USA	1984-1987	PB, CS	IGT	418	*	39.0	White

2

3 **Footnotes:** C, cohort study; CS, cross-sectional study; HA, Hispanic; HB, hospital-based; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; NGT, normal
4 glucose tolerance; NHB, non-Hispanic Black; NHW, non-Hispanic White; nT2DM, new or screen-detected type 2 diabetes mellitus; PB, population-based; PD, prediabetes;
5 T2DM, known type 2 diabetes mellitus. * data not reported; [†] aggregate value including other study groups (e.g., NGT, T2DM); [‡] mean value ± 95% confidence intervals; [§]
6 median value with ranges in brackets; ** prediabetes group defined by HbA1c criteria only.

1 **Table 2. Prevalence of retinopathy in prediabetes from included studies.**

Author	Definition of retinopathy	Photographic method for diagnosis of retinopathy	Definition of prediabetes	Study group(s)	Participants with retinopathy, <i>n</i>	Sample size	Prevalence estimates (%)	Additional outcome data
Hanssen (2020)	ETDRS and ICDRSS	Colour digital	WHO	IFG or IGT	*	478	0.3	*
Callaghan (2020)	*	Non-mydratic colour digital	ADA	IFG or IGT	*	56	1.9	*
Gabriel (2020)	ETDRS ≥ 14	Mydratic, 3-field colour digital	WHO	IFG or IGT	34	809	4.2	*
Sokolowska (2016)	*	Colour digital	*	IFG or IGT	6	61	9.8	*
Penman (2015)	ETDRS ≥ 14	Mydratic, 7-field colour digital	WHO	IGT	25	266	9.4	CSMO: 0% CSMO: 7.8%
Hu (2015)	ETDRS	Dark-adapted, 1-field, 45-degree colour digital	ADA	IFG or IGT	9	657	1.4	*
Bhargava (2014)	ETDRS > 14	Mydratic, 2-field, 45-degree colour digital	ADA	PD**	55	829	6.6	*
Lamparter (2014)	ETDRS	Dark-adapted, 2-field colour digital	ADA	PD**	75	922	8.1	CSMO: 0.2%
Akhter (2013)	ETDRS	Mydratic, 3-field colour digital	WHO	IFG or IGT	7	54	13	*

Bower (2013)	ETDRS ≥ 14	Non-mydiatic, 2-field, 45-degree colour digital	WHO	PD**	*	631	9.7 [†]	*
Dyck (2012)	NSC: R0-R3	7-field colour digital	ADA and WHO	IFG IGT IFG with IGT	*	118 19 37	4.3 9.9 8.7	WHO cut-off for IFG (6.1 mmol/L) but also included abnormal A1c as per ADA
Sundling (2012)	DRDSS: 5 stages	Non-mydiatic, 1-field, 45-degree colour digital	WHO	IGT	1	34	2.9	*
Pang (2011)	DRDSS: G1-4	Dark-adapted, 1-field, 45-degree colour digital	ADA	IGT	22	865	2.5	CSMO: 2.4%
Munch (2011)	ETDRS ≥ 15	Mydiatic, 7-field, 60-degree colour digital	WHO	IFG IGT IFG with IGT	*	59 152 64	14 8 9.5	*
Tyrberg (2008)	Alternative WES-DR ≥ 21	Mydiatic, 2-field, colour film	Non-standard [‡]	IFG	16	154	10.4	*
Tikellis (2007)	Wisconsin	Non-mydiatic, 2-field, 45-degree colour digital	WHO	IFG or IGT	66	960	6.9	*
Kawasaki (2006)	Not defined: any MA, Hg or exudate	Non-mydiatic, 1-field, 45-degree colour digital	WHO	IFG or IGT	*	303	14.1	*
Van Leiden (2002)	EURODIAB: ≥ 1 MA, Hg or hard exudate	Mydiatic, 2-field colour digital	WHO	IGT	*	177	11	HE: 6%
Herman (1998)	Wisconsin	Mydiatic digital	WHO	IGT	*	103	1.9	*
Rajala (1998)	University Hospital of Oulu classification: G1-4	Dark-adapted, 1-field, 45-degree film	WHO (1985)	IGT	*	204	2.0	*

Dowse (1998)	Airlie-House	3-field, 45-degree digital	WHO	IGT	15	165	9.1	PDR: 0%
Nagi (1997)	Modified Airlie-House	Mydriatic, 2-field, 45-degree digital	WHO	IGT	8	288 (incl. NGT)	12.0	*
Collins (1995)	Airlie-House	Mydriatic, 3-field, 45-degree	WHO	IGT	7	97	7.2	PDR: 1.0%
Klein (1991)	Wisconsin ≥ 15	Dark-adapted, 1-field, 45-degree	WHO	IGT	6	418	1.4	*

2

3 **Footnotes:** **ADA**, American Diabetes Association; **CSMO**, clinically-significant macular oedema; **DRDSS**, Diabetic Retinopathy Disease Severity Scale; **ETDRS**, Early
4 Treatment Diabetic Retinopathy Study; **ICDRSS**, International Clinical Diabetic Retinopathy Severity Scale; **HE**, hard exudate; **IFG**, impaired fasting glucose; **IGT**, impaired
5 glucose tolerance; **NGT**, normal glucose tolerance; **NSC**, National Screening Committee (UK); **PD**, prediabetes; **PDR**, proliferative diabetic retinopathy; **WES-DR**, Wisconsin
6 Epidemiologic Study of Diabetic Retinopathy; **WHO**, World Health Organization. * data not reported; † additional data available for ethnicity-specific prevalence figures; ‡
7 IFG defined as ≥ 5.6 and < 6.1 mmol/l; ** prediabetes group defined by HbA1c criteria only.

1 **Table 3. Prevalence of retinopathy in prediabetes from included studies.**

Author	Definition of retinopathy	Photographic method for diagnosis of retinopathy	Definition of prediabetes	Study group(s)	Participants with retinopathy, <i>n</i>	Sample size	Prevalence estimates (%)	Additional outcome data
Hanssen (2020)	ETDRS and ICDRSS	Colour digital	WHO	IFG or IGT	*	478	0.3	*
Callaghan (2020)	*	Non-mydratric colour digital	ADA	IFG or IGT	*	56	1.9	*
Gabriel (2020)	ETDRS ≥ 14	Mydratric, 3-field colour digital	WHO	IFG or IGT	34	809	4.2	*
Sokolowska (2016)	*	Colour digital	*	IFG or IGT	6	61	9.8	*
Penman (2015)	ETDRS ≥ 14	Mydratric, 7-field colour digital	WHO	IGT	25	266	9.4	CSMO: 0% CSMO: 7.8%
Hu (2015)	ETDRS	Dark-adapted, 1-field, 45-degree colour digital	ADA	IFG or IGT	9	657	1.4	*
Bhargava (2014)	ETDRS > 14	Mydratric, 2-field, 45-degree colour digital	ADA	PD**	55	829	6.6	*
Lamparter (2014)	ETDRS	Dark-adapted, 2-field colour digital	ADA	PD**	75	922	8.1	CSMO: 0.2%
Akhter (2013)	ETDRS	Mydratric, 3-field colour digital	WHO	IFG or IGT	7	54	13	*

Bower (2013)	ETDRS ≥ 14	Non-mydiatic, 2-field, 45-degree colour digital	WHO	PD**	*	631	9.7 [†]	*
Dyck (2012)	NSC: R0-R3	7-field colour digital	ADA and WHO	IFG IGT IFG with IGT	*	118 19 37	4.3 9.9 8.7	WHO cut-off for IFG (6.1 mmol/L) but also included abnormal A1c as per ADA
Sundling (2012)	DRDSS: 5 stages	Non-mydiatic, 1-field, 45-degree colour digital	WHO	IGT	1	34	2.9	*
Pang (2011)	DRDSS: G1-4	Dark-adapted, 1-field, 45-degree colour digital	ADA	IGT	22	865	2.5	CSMO: 2.4%
Munch (2011)	ETDRS ≥ 15	Mydiatic, 7-field, 60-degree colour digital	WHO	IFG IGT IFG with IGT	*	59 152 64	14 8 9.5	*
Tyrberg (2008)	Alternative WES-DR ≥ 21	Mydiatic, 2-field, colour film	Non-standard [‡]	IFG	16	154	10.4	*
Tikellis (2007)	Wisconsin	Non-mydiatic, 2-field, 45-degree colour digital	WHO	IFG or IGT	66	960	6.9	*
Kawasaki (2006)	Not defined: any MA, Hg or exudate	Non-mydiatic, 1-field, 45-degree colour digital	WHO	IFG or IGT	*	303	14.1	*
Van Leiden (2002)	EURODIAB: ≥ 1 MA, Hg or hard exudate	Mydiatic, 2-field colour digital	WHO	IGT	*	177	11	HE: 6%
Herman (1998)	Wisconsin	Mydiatic digital	WHO	IGT	*	103	1.9	*
Rajala (1998)	University Hospital of Oulu classification: G1-4	Dark-adapted, 1-field, 45-degree film	WHO (1985)	IGT	*	204	2.0	*

Dowse (1998)	Airlie-House	3-field, 45-degree digital	WHO	IGT	15	165	9.1	PDR: 0%
Nagi (1997)	Modified Airlie-House	Mydriatic, 2-field, 45-degree digital	WHO	IGT	8	288 (incl. NGT)	12.0	*
Collins (1995)	Airlie-House	Mydriatic, 3-field, 45-degree	WHO	IGT	7	97	7.2	PDR: 1.0%
Klein (1991)	Wisconsin ≥ 15	Dark-adapted, 1-field, 45-degree	WHO	IGT	6	418	1.4	*

2

3 **Footnotes:** ADA, American Diabetes Association; CSMO, clinically-significant macular oedema; DRDSS, Diabetic Retinopathy Disease Severity Scale; ETDRS, Early
4 Treatment Diabetic Retinopathy Study; ICDRSS, International Clinical Diabetic Retinopathy Severity Scale; HE, hard exudate; IFG, impaired fasting glucose; IGT, impaired
5 glucose tolerance; NGT, normal glucose tolerance; NSC, National Screening Committee (UK); PD, prediabetes; PDR, proliferative diabetic retinopathy; WES-DR, Wisconsin
6 Epidemiologic Study of Diabetic Retinopathy; WHO, World Health Organization. * data not reported; † additional data available for ethnicity-specific prevalence figures; ‡
7 IFG defined as ≥ 5.6 and < 6.1 mmol/l; ** prediabetes group defined by HbA1c criteria only.

5. STATEMENT OF DISCLOSURE

Each author must complete a statement of disclosure.

Manuscript Title: **The prevalence of retinopathy in prediabetes: a systematic review**

Authors: Varo Kirthi, Paul Nderitu, Uazman Alam, Jennifer Evans, Sarah Nevitt, Rayaz A. Malik, David Hopkins, Timothy L. Jackson

PLEASE LIST:

A) Any commercial or similar relationships of the authors or members of their families to products or companies mentioned in or related to the subject matter of the article being submitted **None**

B) Any source of funding for the article being submitted **None**

C) Any corporate appointments of the authors or members of their families relating to or in connection with products or companies mentioned in the article or otherwise bearing on the subject matter of the article being submitted **None**


D) Any other pertinent financial relationships of the authors or members of their families, such as consultancies, stock ownership or other equity interests or patent-licensing arrangements to products mentioned in the article being submitted **None**

E) Has any portion of this manuscript been submitted for publication elsewhere and/or is it under consideration for publication in another journal, website or textbook? (If yes, please provide details) **No**

=====
All authors must sign to assure that the statements listed above are truthful and complete to the best of their knowledge.

See overleaf

Varo Kirthi



Paul Nderitu




Uazman Alam




Jennifer Evans



Sarah Nevitt



Rayaz A. Malik



David Hopkins



Timothy L. Jackson





[Click here to access/download](#)

e-Component

Revised Supplementary Material.docx



1 **TITLE**

2 The prevalence of retinopathy in prediabetes: A systematic review

3 **AUTHORS**

4 Dr Varo Kirthi FRCOphth ^{1,2}, Dr Paul Nderitu FRCOphth ^{1,2}, Dr Uazman Alam PhD ^{3,4,5}, Dr
5 Jennifer R. Evans PhD ^{6,7}, Dr Sarah Nevitt PhD ³, Prof Rayaz A. Malik FRCP ⁸, Dr David
6 Hopkins FRCP ^{1,2}, Prof Timothy L. Jackson FRCOphth ^{1,2}

7 **Institutions:** ¹ King's College London, London, UK; ² King's College Hospital NHS
8 Foundation Trust, London, UK; ³ University of Liverpool, Liverpool, UK; ⁴ Liverpool
9 University Hospitals NHS Foundation Trust, Liverpool, UK; ⁵ University of Manchester,
10 Manchester, UK; ⁶ London School of Hygiene and Tropical Medicine, London, UK; ⁷ Centre
11 for Public Health, Queen's University Belfast, Belfast, UK. ⁸ Weill Cornell Medicine-Qatar,
12 Doha, Qatar.

13 **Corresponding author:** Dr Varo Kirthi, Department of Ophthalmology, Faculty of Life
14 Sciences and Medicine, Normanby Building, King's College Hospital, London SE5 9RS
15 United Kingdom. Telephone: +44 (0)20 3299 7791. Email: v.kirthi@nhs.net.

16 **KEY WORDS**

17 Prediabetes, impaired fasting glucose, impaired glucose tolerance, retinopathy, prevalence,
18 epidemiology

19 **ABSTRACT**

20 Diabetic retinopathy is a leading cause of vision loss globally. The current diagnostic
21 thresholds for diabetes are still based on historic data correlating glycaemic parameters with
22 retinopathy; however, an excess prevalence of retinopathy has also been reported in
23 prediabetes. We aimed to determine the reported prevalence of retinopathy in adults with
24 prediabetes. We performed searches using MEDLINE, EMBASE, PubMed, Web of Science,
25 CINAHL, Google Scholar and the Cochrane databases from inception to 1 August 2020. We
26 evaluated methodological quality and certainty of the evidence using a validated risk of bias
27 tool and GRADE, respectively. Twenty-four studies (8759 participants with prediabetes) were
28 included after screening 5994 abstracts and reviewing 98 full-text records. Nineteen studies
29 (79%) reported population-based data. Retinopathy prevalence estimates ranged between 0.3-
30 14.1% (median 7.1%, interquartile range 2.4-10.0%), with high variance in estimates due to
31 differing screening methods, retinopathy grading protocols and study populations. We judged
32 this as low-certainty evidence using GRADE, downgrading for risk of bias and inconsistency.
33 From studies that compared both populations, *post hoc* analysis revealed a lower median
34 retinopathy prevalence in normal glucose tolerance (3.2%, interquartile range 0.3-7.3%) than
35 prediabetes (6.6%, interquartile range 1.9-9.8%). These data suggest an excess prevalence of
36 retinopathy in prediabetes.

37 1. INTRODUCTION

38 Prediabetes is defined as suboptimal glycemia that does not reach the threshold for type 2
39 diabetes ^{1,4}. Worldwide, approximately one in 13 adults (374 million) aged 20-79 years have
40 prediabetes, and the vast majority are unaware of the diagnosis ²³. There is a significant
41 predicted burden, with the International Diabetes Federation projecting 587 million people
42 (8.3% of adults) to have prediabetes by 2045 ²³.

43 The World Health Organization (WHO) uses two specific parameters to define prediabetes: (i)
44 impaired fasting glucose (IFG), defined as a fasting plasma glucose (FPG) of 6.1-6.9 mmol/L
45 (110-125 mg/dL) and (ii) impaired glucose tolerance (IGT), defined as a two-hour plasma
46 glucose of 7.8-11.0 mmol/L (140-200 mg/dL) after ingestion of 75g oral glucose, or a
47 combination of the two based on a two-hour oral glucose tolerance test (OGTT) ¹. The
48 American Diabetes Association (ADA) uses the same cut-off value for IGT (140-200 mg/dL),
49 but has a lower cut-off value for IFG (100-125 mg/dL) ⁴. In addition, the ADA includes a
50 haemoglobin A1c (HbA1c) level of 5.7-6.4% to define prediabetes ⁴.

51 Current diagnostic thresholds for fasting and two-hour post-load plasma glucose levels are
52 based on the presence of retinopathy reported in population-based studies in Pima Indians,
53 Egypt, and the United States; ⁵³ however, subsequent studies have failed to confirm these
54 thresholds, attributed to broad definitions of retinopathy and limited statistical power ^{52,61}. The
55 DETECT-2 study showed that diabetic retinopathy (DR) was associated with a fasting plasma
56 glucose of 6.5 mmol/l ¹⁰. Data also suggest that end-organ complications occur prior to the
57 onset of type 2 diabetes ⁵⁰. Compared to individuals with normal glucose tolerance (NGT),
58 those with prediabetes have an increased prevalence of microvascular disease, elevated all-
59 cause mortality, and a doubling of coronary heart disease mortality ^{51,57}. People with

60 prediabetes and concomitant microvascular disease are also more likely to develop type 2
61 diabetes ^{5,30,58}.

62 In people with diabetes, the worldwide prevalence of any DR, proliferative DR, diabetic
63 macular edema and vision-threatening DR is 34.6%, 7.0%, 6.8% and 10.2%, respectively ⁶³.
64 Hence the early diagnosis of sight-threatening disease is key ^{38,50}. Although approaches to
65 population-based screening vary by country, digital retinal photography is considered the most
66 effective screening method for DR ⁶². Although isolated retinopathy occurs with increasing age
67 and hypertension, the prevalence varies between 2.6-8.6% even in individuals without diabetes
68 or hypertension, which may be attributed to prediabetes ^{39,60}. We aimed to determine and
69 discuss the prevalence of retinopathy in prediabetes by undertaking a systematic review of
70 published data, using evidence-based Preferred Reporting Items for Systematic Reviews and
71 Meta-Analyses (PRISMA) guidelines.

72 2. RESULTS

73 **2.1 Study characteristics:** After removal of duplicate entries, we identified 5155 records from
74 the electronic database searches and selected 98 records for full-text review. Of these, 24
75 studies (8759 participants with prediabetes) were included in the final review. Reasons for
76 exclusion after full-text review are shown in Figure 1.

77 Characteristics of the included studies are presented in Table 1. Of the 15 studies that reported
78 age data, 11 reported a mean or median age of participants. Among the 21 studies that reported
79 gender data, gender ratios varied widely from 17.9% to 67.8% male.

80 Studies were conducted in 22 different countries and 6 WHO regions. Eight studies were
81 conducted in Europe, 6 in the Americas (USA), six in the Western Pacific (China, Japan,
82 Singapore, Australia and Samoa), and 1 each in South-East Asia (Bangladesh), Africa
83 (Mauritius) and the Eastern Mediterranean (Egypt). One publication was a multinational study
84 conducted across 9 countries¹⁶. Thirteen studies reported race or ethnicity data, from a wide
85 variety of backgrounds; 2 studies exclusively examined African Americans and Pima Indians,
86 both from the USA^{35,43}. The majority of studies were cross-sectional and population-based
87 (19/24, 79%); three were cross-sectional, hospital-based studies and two were double-blind,
88 randomised-controlled trials reporting baseline prevalence data. Sample sizes for the included
89 studies varied between 34 and 960. Fifteen studies used WHO criteria to define prediabetes,
90 five used ADA criteria, two used non-standard or superseded WHO criteria, 1 failed to report
91 how prediabetes was defined, and 1 study used stricter non-standard IFG criteria⁵⁴.

92 **2.2 Risk of bias assessment:** Points scored on individual risk of bias items and the overall
93 scores of the included studies are provided in Table S1. We deemed the majority of studies
94 (19/24, 79%) 'low' risk whilst the remaining five were deemed 'moderate' risk. The most

95 common issues were: (i) the likelihood of non-response bias due to a response rate <75% (17
96 studies); (ii) the study instrument not shown to have reliability or validity, scored for any study
97 that failed to perform pharmacological mydriasis (14 studies) and (iii) a lack of census or some
98 form of random selection performed to select the sample (9 studies).

99 Owing to variations in study populations, fields captured on retinal photography, retinopathy
100 classifications, use of pharmacological dilation and diagnostic methods for prediabetes, we
101 considered clinical and statistical (I^2 : 93%) heterogeneity too high to perform a meta-analysis
102 ²⁰. Where quantitative data were available, we recorded median estimates and ranges. Where
103 such data were lacking, we conducted a narrative analysis of the data.

104 **2.3 Primary outcome:** A summary of the prevalence data is shown in Figure 2 and Table 2.
105 The median estimated prevalence of retinopathy in prediabetes was 7.1% (interquartile range
106 (IQR): 2.4-9.7%); however, prevalence estimates varied widely, from 0.3% in a study from the
107 Netherlands (n=478) to 14.1% in a study from Japan (n=303) ^{19,26}. The median sample size for
108 the at-risk population with prediabetes was 235 (range 34-960).

109 **2.4 GRADE assessment of primary outcome:** Confidence in the body of evidence for the
110 primary outcome was assessed using the five Grading of Recommendations Assessment,
111 Development and Evaluation (GRADE) domains: (i) risk of bias, (ii) inconsistency, (iii)
112 imprecision, (iv) indirectness and (v) publication bias, summarised in Table S2. Although the
113 overall risk of bias in most studies was low, the majority of studies were at risk of non-response
114 bias and a significant proportion reported non-random sampling methods. There was also
115 evidence of inconsistency due to a wide variation in prevalence estimates, which did not
116 correlate with study settings. Although 95% confidence intervals for most prevalence estimates
117 were wide, given the total number of participants, if data were pooled the overall estimate of

118 prevalence may be reasonably precise. As the majority of studies were population-based and
119 all studies measured the outcome of interest, we found no evidence of indirectness. Although
120 studies of varying sample sizes reported high and low prevalence estimates, we found no
121 evidence of publication bias. We deemed the overall GRADE assessment of the prevalence of
122 retinopathy in prediabetes low certainty, downgrading one level for risk of bias and one level
123 for inconsistency.

124 **2.5 Subgroup analyses of primary outcome:** Where quantitative subgroup data were lacking,
125 we conducted a narrative analysis. As insufficient data were reported, we did not perform an
126 analysis of the time since diagnosis of prediabetes on the prevalence of retinopathy.

127 *2.5.1 WHO region:* Median retinopathy estimates by WHO region were 7.6% (range: 1.4-
128 12.0%) for the Americas, 8.9% (range: 0.3-11.0%) for Europe and 6.8% (range: 1.4-14.1%)
129 for the Western Pacific. Only 1 study contributed to the retinopathy estimates for Africa
130 (9.1%), South-East Asia (13.0%), and the Eastern Mediterranean (1.9%).

131 *2.5.2 Age, gender and ethnicity:* Two studies reported age-specific prevalence estimates in
132 prediabetes. Klein and coworkers recruited participants aged ≥ 55 years and found no increase
133 in retinopathy prevalence with age. Herman and coworkers, however, reported a higher
134 prevalence of retinopathy in those aged ≥ 45 years compared to those aged 20-44 years. One
135 study reported a higher prevalence of retinopathy (Wisconsin grade ≥ 15) in females (2.0%)
136 compared to males (0.5%)²⁸. Similarly, only 1 study compared ethnicity-specific prevalence
137 estimates, with higher rates reported in Hispanic White (10.0%) and non-Hispanic Black
138 (11.6%) individuals, compared to non-Hispanic White individuals (7.5%)⁷. The highest
139 estimated prevalence of retinopathy (14.1%) was reported in a Japanese population²⁶.

140 2.5.3 *Subtype of prediabetes*: Twelve studies presented prevalence estimates for IGT, with a
141 median prevalence of 7.6% (range: 1.9-12.0%). For IFG, the median prevalence of retinopathy
142 was 10.4% (range: 4.3-14%) based on three studies. One study defined the upper limit of IFG
143 as <6.1 mmol/l, compared to ADA and WHO criteria (<7.0 mmol/l) ⁵⁴. Three studies reported
144 prevalence estimates for participants with combined IFG/IGT, with a median prevalence of
145 8.7% (range: 0.3-9.5%). Seven studies reported prevalence estimates for retinopathy amongst
146 participants with IFG or IGT, with a median prevalence of 6.9% (range: 1.4-14.1%).

147 2.5.4 *Grade of retinopathy*: Penman and coworkers reported the prevalence of retinopathy by
148 Early Treatment Diabetic Retinopathy Study (ETDRS) grade ⁴³. Of 266 participants with IGT,
149 the number with retinopathy at ETDRS grades 15, 20 and 35 were 12 (4.5%), 9 (3.4%) and 4
150 (1.5%), respectively. The remaining participants (n=240, 90.2%) had retinopathy at ETDRS
151 grade ≤ 14 . Collins and coworkers (n=97) found one case of proliferative retinopathy in a
152 Samoan population, while Dowse and coworkers (n=165) did not observe any cases among a
153 mixed population of Indian, Creole and Chinese participants ^{11,14}.

154 2.5.5 *Comorbid ocular pathology*: Van Leiden and coworkers (n=165) reported a 6%
155 prevalence of hard exudates among participants with IGT ³¹. Sundling and coworkers (n=38)
156 had 1 participant (2.6%) with hypertensive retinopathy among those with IGT ⁴⁹. There was no
157 difference in the prevalence of glaucoma or age-related macular degeneration in IGT compared
158 to diabetes and NGT. Only 1 study reported the incidence of pseudophakia (4.9%), hence the
159 prevalence of cataract in phakic eyes could not be reliably determined ²⁹.

160 2.5.6 *Comorbid cardiovascular risk factors*: Metabolic data from the included studies are
161 summariszd in Table S3. Six studies reported a median prevalence of 59% (range: 31-73%) for

162 hypertension in prediabetes. Subgroup analysis was not possible owing to a lack of reporting
163 of prevalence estimates stratified by blood pressure.

164 *2.5.7 Method or criteria used to diagnose prediabetes:* The median prevalence estimate was
165 higher among the 15 studies that used WHO criteria (9.1%, range: 0.3-14.1%) compared to
166 five studies that used ADA criteria (2.5%, range: 1.4-8.1%). Data on HbA1c were most
167 commonly available (12 studies), followed by fasting plasma glucose (FPG; 9 studies) and
168 OGTT (9 studies), as summarised in Table S2; subgroup analysis was precluded by a lack of
169 detail on the exact test used to diagnose prediabetes. Three studies using HbA1c criteria alone
170 for the diagnosis of prediabetes reported a median prevalence estimate of 8.1% (range: 6.6-
171 9.7%).

172 *2.5.8 Method used to diagnose retinopathy:* All included studies diagnosed retinopathy on
173 retinal photography, but with a range of methods, from 1-field to 7-field fundus imaging. Ten
174 studies that used pharmacological mydriasis reported the highest median prevalence of
175 retinopathy (9.5%, range: 1.9-13.0%), compared to 5 studies that performed non-mydriatic
176 imaging (6.9%, range: 1.9-14.1%) and 5 studies that obtained images after dark adaptation i.e.
177 physiological mydriasis (2.0%, range: 1.4-8.1%). The remaining studies failed to provide
178 sufficient information on mydriasis status.

179 **2.6 Secondary outcomes:** None of the included studies found any microvascular abnormalities
180 that were not standard features of diabetic retinopathy. Only 3 studies reported the prevalence
181 of maculopathy in prediabetes, based solely on retinal photography. Lamparter and coworkers
182 (n=922) and Pang and coworkers (n=865) determined the prevalence of clinically significant
183 macular edema (CSMO) as 0.2% and 2.4%, respectively ^{29,42}. By contrast Penman and
184 coworkers had no cases of maculopathy ⁴³.

185 **2.7 Post hoc analysis:** Data for all study groups are summarised in Tables S4 and S5. To
186 explore if there is an excess prevalence of retinopathy in prediabetes compared to NGT, we
187 performed an exploratory *post hoc* comparison. Seventeen of the 24 studies also reported
188 prevalence estimates of retinopathy in NGT. From these studies, the median estimated
189 prevalence of retinopathy in prediabetes (6.6%, IQR: 1.9-9.8%) was higher than in NGT (3.2%,
190 IQR: 0.3-7.3%), summarized in Figure S1. Prevalence estimates and sample sizes however
191 varied widely in NGT (0.1-10.3% and 29 to 3970 participants respectively). The majority
192 (13/17 studies, 76%) reported a higher prevalence estimate in prediabetes than NGT.

193 **3. DISCUSSION**

194 **3.1 Summary of retinopathy outcomes:** In this systematic review, we found the median
195 prevalence of retinopathy in prediabetes to be 7.1% (IQR: 2.4-9.7%), with the majority of
196 studies (15/24, 62.5%) reporting a prevalence of $\geq 5\%$ in prediabetes. There was, however,
197 considerable variation in prevalence estimates (0.3-14.1%), particularly between studies that
198 used pharmacological and physiological mydriasis. Despite this variation, on *post hoc* analysis
199 we found a higher median prevalence of retinopathy in prediabetes (6.6%) than NGT (3.2%)
200 within the same studies. We also found a low prevalence of more-than-mild retinopathy or
201 CSMO in prediabetes, although data were limited.

202 **3.2 Comparisons with previous data:** A comparison of retinopathy prevalence estimates
203 between studies was challenging given the varying definitions of dysglycaemia, retinopathy,
204 the influence of hypertension, retinal imaging modalities, study populations and designs^{39,45,50}.
205 Clinical heterogeneity may in part explain the considerable variations in prevalence estimates.
206 Indeed, the level of statistical heterogeneity (I^2 : 93%) was also high, thus a summary estimate
207 of pooled prevalence was not feasible. Overall, the reported excess of retinopathy in
208 prediabetes is in keeping with other retinal and systemic microvascular changes.
209 Microaneurysms, a well characterised DR lesion, occur in 6.9% of participants with impaired
210 glucose metabolism¹³. Isolated retinal lesions occur in 2.6-8.6% of people without diabetes or
211 hypertension, suggesting that dysglycaemia is an important risk factor for the development of
212 retinal vascular changes³⁹. Reported associations between prediabetes and peripheral
213 neuropathy, nephropathy and cardiac autonomic neuropathy provide further evidence of
214 multisystem end-organ dysfunction preceding the onset of type 2 diabetes^{15,48,50}.

215 **3.3 Demographic risk factors:** Risk factors for DR include age, ethnicity, disease duration,
216 and the severity of hyperglycemia ⁶³. The mean ages of participants were similar to those
217 reported in populations with DR ⁶³. A paucity of age-specific retinopathy estimates limited
218 comparisons with prior studies. Only 1 study reported a higher prevalence of retinopathy in
219 females, despite reports of retinopathy being more prevalent in males, with or without diabetes
220 ^{6,41}. One study reported a higher prevalence of retinopathy among non-Hispanic Black
221 participants, similar to data for individuals with diabetes ⁶³.

222 **3.4 HbA1c and comparisons between IFG and IGT:** Estimates for retinopathy varied for
223 IFG, IGT and combined IFG/IGT subgroups, but only 2 studies reported data for all
224 3 subgroups. Although people with combined IFG/IGT are at higher risk of progressing to
225 diabetes (15-19%) compared to isolated IFG (6-9%) or IGT (4-6%), this was not reflected in
226 the retinopathy prevalence estimates reported ⁵⁰. Despite using a narrow range of ≥ 5.6 and < 6.1
227 mmol/L for IFG, Tyrberg and coworkers found a retinopathy prevalence of 10.4% ⁵⁴. Different
228 pathological mechanisms have been postulated in IFG and IGT, based on the origin of insulin
229 resistance reported as predominantly hepatic and muscular, respectively ^{36,50}. This may explain
230 the differences in retinopathy prevalence. HbA1c provides an indication of chronic glycaemia,
231 whereas the OGTT measures glycemia at a single time point. Importantly, HbA1c has a similar
232 relationship to OGTT (fasting and 2-hour plasma glucose), as demonstrated by DETECT-2 ¹⁰.
233 Using HbA1c diagnostic criteria (5.7%-6.4%) alone, annual diabetes incidence rates are
234 broadly similar in IFG and IGT (7%) ⁵⁰.

235 **3.5 Retinopathy severity:** Prediabetes was predominantly associated with early stage
236 retinopathy using ETDRS grades, and the most commonly reported retinal lesions were
237 microaneurysms ¹³. Only 2 studies (n=262) reported the prevalence of proliferative diabetic

238 retinopathy in prediabetes, with 1 affected participant. Similar to diabetes, the risk of
239 microvascular dysfunction increases with the duration of prediabetes ⁴⁴.

240 **3.6 Retinal imaging methods:** Pharmacological mydriasis considerably improves the efficacy
241 of DR screening, with a much lower poor-quality image rate than non-mydriatic fundal imaging
242 (3.7% compared to 19.7%, respectively) ⁴⁵. In our analysis a higher median prevalence of
243 retinopathy was observed after pharmacological mydriasis compared to both no mydriasis and
244 physiological mydriasis. Furthermore, studies that did not use pharmacological mydriasis were
245 given a higher risk of bias score under the ‘study instrument reliability and validity’ domain.
246 The number of retinal fields imaged also varied among studies, which may have affected
247 retinopathy estimates; however, there is an 87% agreement between two- and seven-field
248 (gold-standard) imaging for the detection of any retinopathy ³⁴. While seven-field imaging
249 correlates well with clinical examination by an ophthalmologist, the technical failure rate is
250 higher compared to two-field imaging and ungradable images affect retinopathy detection rates
251 ⁴⁶.

252 **3.7 Comorbid ocular and metabolic disease:** Data on comorbid ocular diseases were limited.
253 Where reported, cataract data were presented without lens status (phakic or pseudophakic).
254 Hypertension and other metabolic syndrome components, including dyslipidaemia and body
255 mass index (BMI), were higher in prediabetes than NGT. While the dynamic relationship
256 between glycemic control and retinal damage are well documented, hypertension is an
257 important contributor to retinopathy ^{12,55,56}. Animal models and human studies suggest that
258 retinal arteriolar endothelial dysfunction and chronic inflammation are common pathological
259 processes underlying both DR and hypertensive retinopathy ^{22,39}; however, data on
260 hypertension-specific retinopathy rates in prediabetes were limited. Dyslipidaemia in
261 prediabetes is characterised by low high-density lipoprotein (HDL) and raised triglycerides

262 (TG) ^{8,25}. One study reported a significantly higher prevalence of metabolic syndrome in
263 severely obese prediabetic participants compared to NGT ¹⁷. Given the high prevalence of
264 metabolic syndrome components in this population, it was unsurprising to note several studies
265 reporting associations with microalbuminuria. The association between retinopathy and
266 dyslipidemia is more variable, with associations reported between hypercholesterolaemia and
267 retinopathy lesions (hard exudates) and also between hypertriglyceridaemia and the risk of DR
268 ^{9,33}.

269 **3.8 Limitations of the current data:** Only 7 studies (29%) had more than 500 participants
270 with six studies (25%) having fewer than 100 participants. Small studies are at risk of reporting
271 bias and prevalence estimates may be less reliable. Prediabetes tests and diagnostic criteria
272 differed between studies with prevalence data on IFG, IGT and combined subgroups from the
273 same participants were provided in only two studies. Because of a high level of clinical
274 heterogeneity from the variety of diagnostic approaches and statistical heterogeneity from
275 variations in study design and methods, we did not perform a meta-analysis; however, where
276 comparisons were made with NGT within the same study, the majority reported higher
277 prevalence estimates in prediabetes than in NGT.

278 **4. CONCLUSIONS**

279 There is an increased prevalence of retinopathy in individuals with prediabetes (median: 7.1%)
280 compared with those with normal glucose tolerance. The current glucocentric thresholds for
281 diabetes fail to capture this burden of subclinical end-organ damage, which affects a sizeable
282 minority of people with prediabetes. With an estimated 10% annual incidence of progression
283 to diabetes and growing evidence of early multisystem involvement ⁵⁰, greater vigilance may
284 be needed to both monitor and mitigate end-organ damage in prediabetes.

285 **5. METHOD OF LITERATURE SEARCH STATEMENT**

286 **5.1 Search strategy:** This systematic review was registered with PROSPERO (CRD:
287 42020184820) and conducted using PRISMA guidelines as per a published protocol ^{27,47}.
288 Comprehensive electronic literature searches were conducted in MEDLINE (via OVID),
289 EMBASE (via OVID), Web of Science, Cumulative Index to Nursing and Allied Health
290 Literature (CINAHL), Google Scholar and the Cochrane databases, from inception to 1 August
291 2020. The search strategies were independently reviewed by an expert information specialist
292 using the Peer Review of Electronic Search Strategies (PRESS) checklist ³². The MEDLINE
293 search strategy is included as an example (Appendix S1). References of included studies and
294 review articles identified during the course of the searches were used to identify any additional
295 articles. Results from the database searches were merged using an electronic reference manager
296 (Rayyan, Qatar Computing Research Institute, Qatar) to facilitate the removal of duplicate
297 articles ⁴⁰.

298 **5.2 Eligibility criteria:** Inclusion criteria were adults aged 18 years or older with prediabetes
299 defined by WHO or ADA criteria ^{1,4}. This included IFG, IGT and combined IFG/IGT as
300 prediabetes subgroups. Population-based cohort or cross-sectional studies from any country in
301 any setting were considered, provided a full-text original manuscript or translation was
302 available in English. Studies were required to report retinopathy prevalence detected on retinal
303 photography, with or without pharmacological mydriasis, using either 1-, 2-, 3- or 7-field
304 colour imaging. A lack of detail on the method used or quality of images taken, or a lack of
305 reporting of the definition of prediabetes or retinopathy were noted, but not considered reasons
306 for exclusion.

307 **5.3 Outcomes:** The primary outcome was the prevalence of any diabetes-specific retinopathy
308 on retinal photography in prediabetes, as per International Clinical Diabetic Retinopathy
309 Severity Scale (ICDRSS) classification ⁵⁹. This was defined by the presence of at least one of
310 the following features on retinal photography:

- 311 (i) Microaneurysms
- 312 (ii) Intraretinal haemorrhages
- 313 (iii) Hard exudates
- 314 (iv) Cotton-wool spots
- 315 (v) Venous beading
- 316 (vi) Intraretinal microvascular abnormalities (IRMAs)
- 317 (vii) New vessels at the optic disc (NVD) or elsewhere (NVE)
- 318 (viii) Vitreous or pre-retinal haemorrhage

319 Secondary outcomes were the prevalence of: (i) any retinal microvascular abnormalities on
320 retinal photography that are not standard features of diabetic retinopathy as per ICDRSS
321 classification, and (ii) any maculopathy on retinal photography in prediabetes.

322 Where available, data on additional imaging, such as fundus fluorescein angiography (FFA) or
323 optical coherence tomography (OCT), were extracted if reported. Data on the method of
324 diagnosing prediabetes and cardiovascular and metabolic parameters were extracted.
325 Metabolic syndrome was defined as per consensus criteria from the WHO, National
326 Cholesterol Education Program Adult Treatment Panel III and ADA ^{1-3,37,64}.

327 **5.4 Study selection and data collection:** Two reviewers independently screened titles and
328 abstracts, excluding any that did not satisfy the eligibility criteria. Disagreements were resolved
329 by discussion, and via third (senior) reviewer arbitration. Articles of interest were selected for

330 full-text assessment; if there was any doubt regarding eligibility, the full-text article was
331 retrieved. Two reviewers independently assessed full-text articles against the eligibility
332 criteria. A PRISMA flowchart is included in Figure 1. Two reviewers independently extracted
333 data using pre-piloted forms. Where reported, secondary outcome data including: (i) the
334 definition and prevalence of non-standard retinopathy features and (ii) the definition and
335 prevalence of maculopathy features, were recorded. Prevalence estimates for co-morbid ocular
336 pathology (e.g., cataract) and cardiovascular risk factors (e.g., hypertension, metabolic
337 syndrome) were also recorded.

338 **5.5 Risk of bias assessment:** All eligible studies were assessed using a modified critical
339 appraisal tool (Appendix S2). The tool features nine questions, each scoring 0 or 1, to assess
340 selection, non-response, measurement and data analysis biases ²¹. Quality assessment was
341 conducted by two reviewers independently, with disagreements resolved by discussion.
342 Judgments on the overall risk of bias were based on the total score for each article: 0-3
343 considered 'low', 4-6 considered 'moderate' and ≥ 7 considered 'high risk', based on the
344 reviewers' subjective judgment of the preceding nine items ²¹.

345 **5.6 Data analysis:** Data were analysed using Review Manager 5 (The Cochrane Collaboration,
346 Copenhagen, Denmark) and Microsoft Excel 2016 (Microsoft, Redmond, USA). Heterogeneity
347 between included studies was assessed on study design, populations and methods used to
348 measure outcomes. Statistical heterogeneity was assessed using the I^2 statistic and by visual
349 inspection of forest plots ²⁰. Subgroup analyses of the primary outcome were conducted on the
350 following covariates: (i) WHO region; (ii) age, gender, ethnicity; (iii) time since diagnosis of
351 prediabetes; (iv) subtype of prediabetes (e.g., IGT); (v) grade of retinopathy; (vi) comorbid
352 ocular pathology (e.g., cataract); (vii) comorbid cardiovascular risk factors (e.g., hypertension);

353 (viii) method or criteria used to diagnose prediabetes and (ix) method used to diagnose
354 retinopathy.

355 **5.7 Grading of evidence:** The certainty of the evidence was assessed using the GRADE
356 approach, detailed in Table S1^{18,24}.

357 **KEY REFERENCES**

358 **11. Colagiuri S, Lee CMY, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K, et al.**
359 **Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria**
360 **for diabetes. *Diabetes Care*. 2011 Jan 1;34(1):145–50.**

361 The DETECT-2 study, which suggested that the fasting plasma glucose threshold for type 2
362 diabetes could be lowered to 6.5 mmol/l based on the presence of diabetes-specific retinopathy.

363 **25. International Diabetes Federation. International Diabetes Federation Atlas (9th**
364 **Edition). 2019 [cited 2020 May 1]; Available from: <https://www.diabetesatlas.org/>**

365 The IDF Atlas provides an up-to-date global perspective of diabetes and prediabetes.

366 **29. Kirthi V, Nderitu P, Alam U, Evans J, Nevitt S, Malik RA, et al. Prevalence of**
367 **retinopathy in prediabetes: protocol for a systematic review and meta-analysis. *BMJ***
368 **Open. 2021 Jan 7;11(1):e040997.**

369 The peer-reviewed protocol for this systematic review.

370 **HIGHLIGHTS**

- 371 • This systematic review found the prevalence of retinopathy in prediabetes was 7.1%.
- 372 • This represents an excess prevalence versus those with normoglycaemia.
- 373 • Hyperglycaemia can cause retinal damage prior to the diagnosis of diabetes.

374 **CONTRIBUTION STATEMENT**

375 All authors meet the ICMJE uniform requirements for authorship. VK, JE, UA, RAM and TLJ
376 conceived the topic of this systematic review. VK and PN designed the search strategies,
377 reviewed by an expert information specialist (IG), JE and SN. VK and PN performed the
378 searches, data collection and data extraction with senior oversight from UA, JE and SN. SN
379 provided statistical oversight of the data analysis. All authors were involved in the drafting,
380 revision and final approval of the article to be published.

381 **ACKNOWLEDGEMENTS**

382 We are grateful to Iris Gordon, Information Specialist for the Cochrane Eyes and Vision Group,
383 for her independent appraisal of the search strategies performed in this systematic review.

384 **FUNDING**

385 This research received no specific grant from any funding agency in the public, commercial or
386 not-for-profit sectors.

387 **DECLARATION OF INTEREST**

388 The authors report no proprietary or commercial interest in any product mentioned or concept
389 discussed in this article.

390 **DATA AVAILABILITY**

391 All data generated or analysed during this study are included in this published article and its
392 accompanying electronic supplementary material file.

393 **REFERENCES**

- 394 1. Alberti K, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its
395 complications. Part 1: diagnosis and classification of diabetes mellitus provisional report
396 of a WHO consultation. *Diabet Med J Br Diabet Assoc.* 1998;15(7):539-553.
397 doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
- 398 2. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a
399 joint interim statement of the International Diabetes Federation Task Force on
400 Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American
401 Heart Association; World Heart Federation; International Atherosclerosis Society; and
402 International Association for the Study of Obesity. *Circulation.* 2009;120(16):1640-
403 1645. doi:10.1161/CIRCULATIONAHA.109.192644
- 404 3. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of
405 Medical Care in Diabetes-2018. *Diabetes Care.* 2018;41(Suppl 1):S13-S27.
406 doi:10.2337/dc18-S002
- 407 4. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus.
408 *Diabetes Care.* 2010;33(Suppl 1):S62-S69. doi:10.2337/dc10-S062
- 409 5. Azmi S, Ferdousi M, Petropoulos IN, et al. Corneal confocal microscopy identifies small-
410 fiber neuropathy in subjects with impaired glucose tolerance who develop type 2
411 diabetes. *Diabetes Care.* 2015;38(8):1502-1508. doi:10.2337/dc14-2733
- 412 6. Bertelsen G, Peto T, Lindekleiv H, et al. Sex differences in risk factors for retinopathy in
413 non-diabetic men and women: the Tromsø Eye Study. *Acta Ophthalmol (Copenh).*
414 2014;92(4):316-322. doi:10.1111/aos.12199
- 415 7. Bower JK, Brancati FL, Selvin E. No ethnic differences in the association of glycated
416 hemoglobin with retinopathy: the national health and nutrition examination survey
417 2005-2008. *Diabetes Care.* 2013;36(3):569-573. doi:10.2337/dc12-0404
- 418 8. Chakarova N, Tankova T, Atanassova I, Dakovska L. Serum lipid and hsCRP levels in
419 prediabetes--impaired fasting glucose (IFG) and impaired glucose tolerance (IGT).
420 *Diabetes Res Clin Pract.* 2009;86(1):56-60. doi:10.1016/j.diabres.2009.04.005
- 421 9. Chew EY, Klein ML, Ferris FL, et al. Association of elevated serum lipid levels with
422 retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy
423 Study (ETDRS) Report 22. *Arch Ophthalmol Chic Ill 1960.* 1996;114(9):1079-1084.
424 doi:10.1001/archopht.1996.01100140281004
- 425 10. Colagiuri S, Lee CMY, Wong TY, et al. Glycemic thresholds for diabetes-specific
426 retinopathy: implications for diagnostic criteria for diabetes. *Diabetes Care.*
427 2011;34(1):145-150. doi:10.2337/dc10-1206
- 428 11. Collins VR, Dowse GK, Plehwe WE, et al. High prevalence of diabetic retinopathy and
429 nephropathy in Polynesians of Western Samoa. *Diabetes Care.* 1995;18(8):1140-1149.
430 doi:10.2337/diacare.18.8.1140
- 431 12. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al.
432 The effect of intensive treatment of diabetes on the development and progression of

- 433 long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med.*
 434 1993;329(14):977-986. doi:10.1056/NEJM199309303291401
- 435 13. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired
 436 glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. *Diabet*
 437 *Med J Br Diabet Assoc.* 2007;24(2):137-144. doi:10.1111/j.1464-5491.2007.02043.x
- 438 14. Dowse GK, Humphrey AR, Collins VR, et al. Prevalence and risk factors for diabetic
 439 retinopathy in the multiethnic population of Mauritius. *Am J Epidemiol.*
 440 1998;147(5):448-457. doi:10.1093/oxfordjournals.aje.a009470
- 441 15. Eleftheriadou A, Williams S, Nevitt S, et al. The prevalence of cardiac autonomic
 442 neuropathy in prediabetes: a systematic review. *Diabetologia.* 2020;(in press).
- 443 16. Gabriel R, Boukichou Abdelkader N, Acosta T, et al. Early prevention of diabetes
 444 microvascular complications in people with hyperglycaemia in Europe. ePREDICE
 445 randomized trial. Study protocol, recruitment and selected baseline data. *PloS One.*
 446 2020;15(4):e0231196. doi:10.1371/journal.pone.0231196
- 447 17. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. *J Am Coll*
 448 *Cardiol.* 2012;59(7):635-643. doi:10.1016/j.jacc.2011.08.080
- 449 18. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating
 450 quality of evidence and strength of recommendations. *BMJ.* 2008;336(7650):924-926.
 451 doi:10.1136/bmj.39489.470347.AD
- 452 19. Hanssen NMJ, Scheijen JLJM, Houben AJHM, et al. Fasting and post-oral-glucose-load
 453 levels of methylglyoxal are associated with microvascular, but not macrovascular,
 454 disease in individuals with and without (pre)diabetes: The Maastricht Study. *Diabetes*
 455 *Metab.* Published online February 10, 2020. doi:10.1016/j.diabet.2020.02.002
- 456 20. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
 457 analyses. *BMJ.* 2003;327(7414):557-560. doi:10.1136/bmj.327.7414.557
- 458 21. Hoy D, Brooks P, Woolf A, et al. Assessing risk of bias in prevalence studies:
 459 modification of an existing tool and evidence of interrater agreement. *J Clin Epidemiol.*
 460 2012;65(9):934-939. doi:10.1016/j.jclinepi.2011.11.014
- 461 22. Huang Z, Chen C, Li S, Kong F, Shan P, Huang W. Serum markers of endothelial
 462 dysfunction and inflammation increase in hypertension with prediabetes mellitus. *Genet*
 463 *Test Mol Biomark.* 2016;20(6):322-327. doi:10.1089/gtmb.2015.0255
- 464 23. International Diabetes Federation. International Diabetes Federation Atlas (9th Edition).
 465 Published online 2019. Accessed May 1, 2020. <https://www.diabetesatlas.org/>
- 466 24. Iorio A, Spencer FA, Falavigna M, et al. Use of GRADE for assessment of evidence
 467 about prognosis: rating confidence in estimates of event rates in broad categories of
 468 patients. *BMJ.* 2015;350:h870. doi:10.1136/bmj.h870
- 469 25. Kansal S, Kamble TK. Lipid Profile in Prediabetes. *J Assoc Physicians India.*
 470 2016;64(3):18-21.

- 471 26. Kawasaki R, Wang JJ, Rochtchina E, et al. Cardiovascular risk factors and retinal
472 microvascular signs in an adult Japanese population: the Funagata Study.
473 *Ophthalmology*. 2006;113(8):1378-1384. doi:10.1016/j.ophtha.2006.02.052
- 474 27. Kirthi V, Nderitu P, Alam U, et al. Prevalence of retinopathy in prediabetes: protocol for
475 a systematic review and meta-analysis. *BMJ Open*. 2021;11(1):e040997.
476 doi:10.1136/bmjopen-2020-040997
- 477 28. Klein R, Barrett-Connor EL, Blunt BA, Wingard DL. Visual impairment and retinopathy
478 in people with normal glucose tolerance, impaired glucose tolerance, and newly
479 diagnosed NIDDM. *Diabetes Care*. 1991;14(10):914-918.
480 doi:10.2337/diacare.14.10.914
- 481 29. Lamparter J, Raum P, Pfeiffer N, et al. Prevalence and associations of diabetic
482 retinopathy in a large cohort of prediabetic subjects: the Gutenberg Health Study. *J*
483 *Diabetes Complications*. 2014;28(4):482-487. doi:10.1016/j.jdiacomp.2014.02.008
- 484 30. Lee CC, Perkins BA, Kayaniyil S, et al. Peripheral neuropathy and nerve dysfunction in
485 individuals at high risk for type 2 diabetes: The PROMISE Cohort. *Diabetes Care*.
486 2015;38(5):793-800. doi:10.2337/dc14-2585
- 487 31. van Leiden HA, Dekker JM, Moll AC, et al. Blood pressure, lipids, and obesity are
488 associated with retinopathy: the Hoorn study. *Diabetes Care*. 2002;25(8):1320-1325.
489 doi:10.2337/diacare.25.8.1320
- 490 32. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer
491 Review of Electronic Search Strategies: 2015 guideline statement. *J Clin Epidemiol*.
492 2016;75:40-46. doi:10.1016/j.jclinepi.2016.01.021
- 493 33. Modjtahedi BS, Bose N, Papakostas TD, Morse L, Vavvas DG, Kishan AU. Lipids and
494 diabetic retinopathy. *Semin Ophthalmol*. 2016;31(1-2):10-18.
495 doi:10.3109/08820538.2015.1114869
- 496 34. Moss SE, Meuer SM, Klein R, Hubbard LD, Brothers RJ, Klein BE. Are seven standard
497 photographic fields necessary for classification of diabetic retinopathy? *Invest*
498 *Ophthalmol Vis Sci*. 1989;30(5):823-828.
- 499 35. Nagi DK, Pettitt DJ, Bennett PH, Klein R, Knowler WC. Diabetic retinopathy assessed
500 by fundus photography in Pima Indians with impaired glucose tolerance and NIDDM.
501 *Diabet Med J Br Diabet Assoc*. 1997;14(6):449-456. doi:10.1002/(SICI)1096-
502 9136(199706)14:6<449::AID-DIA367>3.0.CO;2-D
- 503 36. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired
504 glucose tolerance: implications for care. *Diabetes Care*. 2007;30(3):753-759.
505 doi:10.2337/dc07-9920
- 506 37. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,
507 and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third
508 Report of the National Cholesterol Education Program (NCEP) Expert Panel on
509 Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult
510 Treatment Panel III) final report. *Circulation*. 2002;106(25):3143-3421.

- 511 38. National Eye Institute. People with diabetes can prevent vision loss. Published online
512 2019. Accessed August 1, 2020. [https://www.nei.nih.gov/sites/default/files/2019-](https://www.nei.nih.gov/sites/default/files/2019-06/diabetes-prevent-vision-loss.pdf)
513 06/diabetes-prevent-vision-loss.pdf
- 514 39. Nguyen TT, Wang JJ, Wong TY. Retinal vascular changes in pre-diabetes and
515 prehypertension: new findings and their research and clinical implications. *Diabetes*
516 *Care*. 2007;30(10):2708-2715. doi:10.2337/dc07-0732
- 517 40. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan - a web and mobile app
518 for systematic reviews. *Syst Rev*. 2016;(5):210. doi:10.1186/s13643-016-0384-4
- 519 41. Ozawa GY, Bearse MA, Adams AJ. Male-female differences in diabetic retinopathy?
520 *Curr Eye Res*. 2015;40(2):234-246. doi:10.3109/02713683.2014.958500
- 521 42. Pang C, Jia L, Jiang S, et al. Determination of diabetic retinopathy prevalence and
522 associated risk factors in Chinese diabetic and pre-diabetic subjects: Shanghai diabetic
523 complications study. *Diabetes Metab Res Rev*. 2012;28(3):276-283.
524 doi:10.1002/dmrr.1307
- 525 43. Penman A, Hoadley S, Wilson JG, Taylor HA, Chen CJ, Sobrin L. P-selectin plasma
526 levels and genetic variant associated with diabetic retinopathy in African Americans.
527 *Am J Ophthalmol*. 2015;159(6):1152-1160.e2. doi:10.1016/j.ajo.2015.03.008
- 528 44. Reis JP, Allen NB, Bancks MP, et al. Duration of diabetes and prediabetes during
529 adulthood and subclinical atherosclerosis and cardiac dysfunction in middle age: the
530 CARDIA study. *Diabetes Care*. 2018;41(4):731-738. doi:10.2337/dc17-2233
- 531 45. Scanlon PH. The English National Screening Programme for diabetic retinopathy 2003-
532 2016. *Acta Diabetol*. 2017;54(6):515-525. doi:10.1007/s00592-017-0974-1
- 533 46. Scanlon PH, Malhotra R, Greenwood RH, et al. Comparison of two reference standards
534 in validating two field mydriatic digital photography as a method of screening for
535 diabetic retinopathy. *Br J Ophthalmol*. 2003;87(10):1258-1263.
536 doi:10.1136/bjo.87.10.1258
- 537 47. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review
538 and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*.
539 2015;350:g7647. doi:10.1136/bmj.g7647
- 540 48. Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. *The Neurologist*.
541 2008;14(1):23-29. doi:10.1097/NRL.0b013e31815a3956
- 542 49. Sundling V, Platou CGP, Jansson RW, Bertelsen G, Wøllo E, Gulbrandsen P.
543 Retinopathy and visual impairment in diabetes, impaired glucose tolerance and normal
544 glucose tolerance: the Nord-Trøndelag Health Study (the HUNT study). *Acta*
545 *Ophthalmol (Copenh)*. 2012;90(3):237-243. doi:10.1111/j.1755-3768.2010.01998.x
- 546 50. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk
547 state for diabetes development. *The Lancet*. 2012;379(9833):2279-2290.
548 doi:10.1016/S0140-6736(12)60283-9

- 549 51. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of
550 glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes:
551 an analysis from the Whitehall II study. *Lancet Lond Engl.* 2009;373(9682):2215-2221.
552 doi:10.1016/S0140-6736(09)60619-X
- 553 52. Tapp RJ, Zimmet PZ, Harper CA, et al. Diagnostic thresholds for diabetes: the
554 association of retinopathy and albuminuria with glycaemia. *Diabetes Res Clin Pract.*
555 2006;73(3):315-321. doi:10.1016/j.diabres.2006.02.008
- 556 53. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report
557 of the Expert Committee on the diagnosis and classification of diabetes mellitus.
558 *Diabetes Care.* 1997;20(7):1183-1197. doi:10.2337/diacare.20.7.1183
- 559 54. Tyrberg M, Melander A, Lövestam-Adrian M, Lindblad U. Retinopathy in subjects with
560 impaired fasting glucose: the NANSY-Eye baseline report. *Diabetes Obes Metab.*
561 2008;10(8):646-651. doi:10.1111/j.1463-1326.2007.00759.x
- 562 55. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared
563 with conventional treatment and risk of complications in patients with type 2 diabetes
564 (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet Lond Engl.*
565 1998;352(9131):837-853.
- 566 56. UKPDS Group. Tight blood pressure control and risk of macrovascular and
567 microvascular complications in type 2 diabetes: UKPDS 38. *BMJ.* 1998;317(7160):703-
568 713. doi:10.1136/bmj.317.7160.703
- 569 57. Vistisen D, Witte DR, Brunner EJ, et al. Risk of cardiovascular disease and death in
570 individuals with prediabetes defined by different criteria: the Whitehall II study.
571 *Diabetes Care.* 2018;41(4):899-906. doi:10.2337/dc17-2530
- 572 58. Wagner R, Heni M, Tabák AG, et al. Pathophysiology-based subphenotyping of
573 individuals at elevated risk for type 2 diabetes. *Nat Med.* Published online January 4,
574 2021. doi:10.1038/s41591-020-1116-9
- 575 59. Wilkinson CP, Ferris FL, Klein RE, et al. Proposed international clinical diabetic
576 retinopathy and diabetic macular edema disease severity scales. *Ophthalmology.*
577 2003;110(9):1677-1682. doi:10.1016/S0161-6420(03)00475-5
- 578 60. Wong TY, Klein R, Sharrett AR, et al. The prevalence and risk factors of retinal
579 microvascular abnormalities in older persons: The Cardiovascular Health Study.
580 *Ophthalmology.* 2003;110(4):658-666. doi:10.1016/S0161-6420(02)01931-0
- 581 61. Wong TY, Liew G, Tapp RJ, et al. Relation between fasting glucose and retinopathy for
582 diagnosis of diabetes: three population-based cross-sectional studies. *Lancet Lond Engl.*
583 2008;371(9614):736-743. doi:10.1016/S0140-6736(08)60343-8
- 584 62. World Health Organization. Diabetic retinopathy screening: a short guide. Published
585 online July 2, 2021. Accessed February 1, 2022.
586 <https://apps.who.int/iris/bitstream/handle/10665/336660/9789289055321-eng.pdf>
- 587 63. Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of
588 diabetic retinopathy. *Diabetes Care.* 2012;35(3):556-564. doi:10.2337/dc11-1909

589 64. Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in
590 adults. *Obes Facts*. 2015;8(6):402-424. doi:10.1159/000442721

591

592 **TABLE AND FIGURE LEGENDS**

593 **Table 1. Characteristics of included studies.**

594 **Footnotes:** C, cohort study; CS, cross-sectional study; HA, Hispanic; HB, hospital-based; IFG, impaired fasting
595 glucose; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; NHB, non-Hispanic Black; NHW,
596 non-Hispanic White; nT2DM, new or screen-detected type 2 diabetes mellitus; PB, population-based; PD,
597 prediabetes; T2DM, known type 2 diabetes mellitus. * data not reported; † aggregate value including other study
598 groups (e.g., NGT, T2DM); ‡ mean value ± 95% confidence intervals; § median value with ranges in brackets; **
599 prediabetes group defined by HbA1c criteria only.

600 **Table 2. Prevalence of retinopathy in prediabetes from included studies.**

601 **Footnotes:** ADA, American Diabetes Association; CSMO, clinically-significant macular oedema; DRDSS,
602 Diabetic Retinopathy Disease Severity Scale; ETDRS, Early Treatment Diabetic Retinopathy Study; ICDRSS,
603 International Clinical Diabetic Retinopathy Severity Scale; HE, hard exudate; IFG, impaired fasting glucose;
604 IGT, impaired glucose tolerance; NGT, normal glucose tolerance; NSC, National Screening Committee (UK);
605 PD, prediabetes; PDR, proliferative diabetic retinopathy; WES-DR, Wisconsin Epidemiologic Study of Diabetic
606 Retinopathy; WHO, World Health Organization. * data not reported; † additional data available for ethnicity-
607 specific prevalence figures; ‡ IFG defined as ≥ 5.6 and < 6.1 mmol/l; ** prediabetes group defined by HbA1c
608 criteria only.

609 **Figure 1. PRISMA flowchart of study selection process.**

610 **Figure 2. Forest plot of the prevalence of retinopathy in prediabetes from included**
611 **studies.**

612 **Footnotes:** * Prediabetes group size estimated from reported retinopathy prevalence and number of affected
613 individuals. ** Aggregate prevalence estimates presented for impaired fasting glucose (IFG), impaired glucose
614 tolerance (IGT) and combined impaired fasting glucose with impaired glucose tolerance (IFG-IGT), (CI)
615 confidence interval. All studies are population-based, except three hospital-based studies (blue highlights) and
616 two randomised-controlled trials (green highlights). Box size proportional to precision.

617 **Figure 3. Forest plot of the prevalence of retinopathy in prediabetes and normal glucose**
618 **tolerance from included studies reporting data for both groups.**

619 **Footnotes:** Normal glucose tolerance (NGT) prevalence estimates in blue, prediabetes prevalence estimates in
620 red. ^a Prediabetes group size estimated from reported retinopathy prevalence and number of affected individuals.
621 ^b Impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and combined impaired fasting glucose with
622 impaired glucose tolerance (IFG/IGT) retinopathy prevalence estimates aggregated with total prediabetes group
623 size used for 95% confidence interval (CI) estimation. ^c NGT group size estimated from the total study sample
624 minus the reported prediabetes population. ^d Prediabetes group size estimated from reported retinopathy
625 prevalence and number of affected individuals. All studies are population-based, except two hospital-based studies
626 (blue highlights). Box size proportional to precision.